                    ⢭⚄ಖ೺◊✲ᡤᖺሗ ➨36ྕ                   7㸬⢭⚄⑌ᝈ⑓ែ◊✲㒊Ϩ㸬◊✲㒊ࡢᴫせ⢭⚄⑌ᝈ⑓ែ◊✲㒊࡛ࡣ㸪⢭⚄⑌ᝈࡢඞ᭹࡜ࡑࡢ㞀ᐖࡢᨭ᥼ࡢࡓࡵࡢඛ㥑ⓗ◊✲άືࢆᒎ㛤ࡋ࡚࠸ࡿ㸬⢭⚄⑌ᝈࡢ⏕≀Ꮫⓗ࡞◊✲࡜⢭⚄⛉἞⒪࢞࢖ࢻࣛ࢖ࣥࡢᬑཬ࣭ᩍ⫱᳨࣭ドάືࢆࡼࡾⓎᒎࡉࡏ࡚඲ᅜ࡛ࣞ࣋ࣝᒎ㛤ࡍࡿࡇ࡜ࢆ┠ᶆ࡜ࡋ࡚࠸ࡿ㸬⢭⚄⑌ᝈࡢ⏕≀Ꮫⓗ࡞◊✲ࡣ㸪ㄆ▱♫఍ᶵ⬟㸪⬻⚄⤒⏬ീ㸪⚄⤒⏕⌮ᶵ⬟࡞࡝ࡢ୰㛫⾲⌧ᆺཬࡧࢤࣀ࣒࡞࡝ࡢ⏕యヨᩱࢆ⏝࠸࡚㸪⤫ྜኻㄪ⑕㸪Ẽศ㞀ᐖ㸪Ⓨ㐩㞀ᐖ࡞࡝ࡢᖜᗈ࠸⢭⚄⑌ᝈ࡟ࡘ࠸࡚⑌ᝈᶓ᩿ⓗ࡟᳨ウࡍࡿࡇ࡜࡟
ࡼࡾ㸪⑓ែࢆゎ᫂ࡋ㸪᪂ࡓ࡞デ᩿ἲ࣭἞⒪ἲࡢ㛤Ⓨࢆ⾜ࡗ࡚࠸ࡿ㸬ࡇࡢ◊✲ࡣ㸪ᙜ◊✲㒊࡟࠾࠸࡚ࡢࡳ⾜࠺ࡶࡢ࡛ࡣ࡞ࡃ㸪ᅜ❧⢭⚄࣭⚄⤒་⒪◊✲ࢭࣥࢱ࣮ࡢ௚ࡢ◊✲㒊㛛࠾ࡼࡧ᪥ᮏ඲ᅜ
42 ࡢ ⢭ ⚄ ⑌ ᝈ 㛵 㐃 ◊ ✲ ᶵ 㛵 ࡢ ඹ ྠ ◊ ✲ య ไ ࡛ ࠶ ࡿ COCORO 㸦 Cognitive Genetics
Collaborative Research Organization㸸ㄆ▱ࢤࣀ࣒ඹྠ◊✲ᶵᵓ㸧ࢆ㐠Ⴀࡋ࣮࢜ࣝࢪࣕࣃࣥయ
ไ࡛㐙⾜ࡋ࡚࠸ࡿ㸬⢭⚄⛉἞⒪࢞࢖ࢻࣛ࢖ࣥࡢᬑཬ࣭ᩍ⫱᳨࣭ドάືࡣ㸪EGUIDE ࣉࣟࢪ࢙ࢡ
ࢺ㸦Effectiveness of GUIdeline for Dissemination and Education in psychiatric treatment㸸⢭⚄⛉་⒪ࡢᬑཬ࡜ᩍ⫱࡟ᑐࡍࡿ࢞࢖ࢻࣛ࢖ࣥࡢຠᯝ࡟㛵ࡍࡿ◊✲㸧࡜࠸࠺඲ᅜ 45 ኱Ꮫࢆྵ
ࡴ 282 ་⒪ᶵ㛵ࡢඹྠ◊✲⤌⧊ࢆ≌ᘬࡋ㸪඲ᅜ࡛࢞࢖ࢻࣛ࢖ࣥࡢㅮ⩦ࢆ⾜࠸㸪ࡑࡢຠᯝ᳨ドࢆ⾜ࡗ࡚࠸ࡿ㸬
௧࿴ 4 ᖺᗘࡢேဨᵓᡂࡣḟࡢ࡜࠾ࡾ࡛࠶ࡿ㸬㒊㛗㸸ᶫᮏுኴ㸪ᐊ㛗㸸୕ᾆ೺୍㑻㸪ᯇᮏ⣧ᘺ㸪ࣜࢧ࣮ࢳࣇ࢙࣮ࣟ㸸㛗㇂ᕝᑦ⨾㸪⛉◊㈝ᚰ⌮⒪ἲኈ㸸⏣ᮧ཭㔛Ụ㸪ᑠụ᫓⳯㸪᪂㇂ⱸⳀᯝ㸪℧
ᾉ㈗ክ࣮࢞ࢿࣦ࢕࢝ࢫ㸪⛉◊㈝◊✲⿵ຓဨ㸸ᮌᮧဴஓ㸪໭ᕝ ⯟㸪ᒣ⦩┾⨾Ꮚ㸪ఀ⸨㣁ጲ㸪ᐑᒣᮍ᮶஀㸪Ἑୖඃ⛥㸪ే௵◊✲ဨ㸸ஂಖ⏣ᬛ㤶㸪బ⸨ⱥᶞ㸪ᐑᕝ ᕼ㸪᯽ᮌᏹᏊ㸪➉⏣ᗣ஧㸪㧘㔝ᬕᡂ㸪▼ᕝኟ⤮㸪ᯘ ኱♸㸪୍ᡞ⣖Ꮥ㸪Ώ㑓 ᝴㸪ᵽཱྀ᪩Ꮚ㸪஬༑ᔒ ಇ㸪すᮧ᫭ⴌ㸪እ᮶◊✲ဨ
15 ྡ㸪ᐈဨ◊✲ဨ 58 ྡ㸪◊✲⏕ 16 ྡ㸬ϩ㸬◊✲άື
㸿㸬⢭⚄⑌ᝈࡢ⑓ែゎ᫂࡜デ᩿ἲ࣭἞⒪ἲࡢ㛤Ⓨ◊✲㸧 ⢭⚄⑌ᝈࡢ⬻⚄⤒⏬ീ◊✲㸦ᯇᮏ㸪୕ᾆ㸪ᶫᮏ㸪㧘㔝㸪ఀ⸨㸪ᐑᒣ㸪ᐑᕝ㸧⢭⚄⑌ᝈࡢ⬻⚄⤒⏬ീ◊✲ࡣ㸪COCORO ࡢ୺࡞࣓ࣥࣂ࣮࡛࠶ࡿ኱㜰኱Ꮫ㸦⸨ᮏ㸪ᒣ᳃㸪Ᏻ⏣ᐈဨ◊✲ဨ㸧㸪⏕⌮Ꮫ◊✲ᡤ㸦⚟Ọᐈဨ◊✲ဨ㸧㸪⟃Ἴ኱Ꮫ㸦᰿ᮏᐈဨ◊✲ဨ㸧㸪ᮾி኱Ꮫ㸦ᒸ⏣ᐈဨ◊✲ဨ㸧㸪໭ᾏ㐨኱Ꮫ㸦ᶫᮏ┤ᶞᐈဨ◊✲ဨ㸧㸪ᒣཱྀ኱Ꮫ㸦୰ᕝᐈဨ◊✲ဨ㸧㸪ி㒔኱Ꮫ㸦ᐑ⏣ᐈဨ◊✲ဨ㸧㸪ᐩᒣ኱Ꮫ㸦㧗ᶫᐈဨ◊✲ဨ㸧㸪ྡྂᒇ኱Ꮫ㸦ᑿᓮᐈဨ◊✲ဨ㸧㸪ᒱ㜧኱Ꮫ㸦኱஭ᐈဨ◊✲ဨ㸧㸪஑ᕞ኱Ꮫ㸦㨣ሯᐈဨ◊✲ဨ㸧㸪᫛࿴኱Ꮫ㸦୰ᮧᐈဨ◊✲ဨ㸧㸪ᚨᓥ኱Ꮫ㸦἟⏣ᐈဨ◊✲ဨ㸧㸪⏘ᴗ་⛉኱Ꮫ㸦ྜྷᮧᐈဨ◊✲ဨ㸧㸪ዉⰋ་⛉኱Ꮫ㸦∾அẁᐈဨ◊✲ဨ㸧㸪ឿᜨ་⛉኱Ꮫ
㸦ᑠ㧗ᐈဨ◊✲ဨ㸧㸪ᗈᓥ኱Ꮫ㸪᪥ᮏ་⛉኱Ꮫ࡞࡝ࡢከ᪋タඹྠ◊✲࡟࡚⾜ࡗ࡚࠸ࡿ㸬⤫ྜኻㄪ⑕ࢆ୰ᚰ࡟୕ḟඖ⬻ᵓ㐀⏬ീゎᯒ㸪ᣑᩓࢸࣥࢯࣝ⏬ീゎᯒ㸪Ᏻ㟼᫬ᶵ⬟ⓗ MRI ゎᯒ࡞࡝ࢆ⾜ࡗ࡚࠸ࡿ㸬ࡲࡓ㸪⬻⑓ែ⤫ྜ࢖࣓࣮ࢪࣥࢢࢭࣥࢱ࣮㸦IBIC㸧⮫ᗋ⬻⏬ീ◊✲㒊ࡢ㧗㔝㒊㛗࡜ඹ࡟㸪Integrative Brain Imaging Support System㸦IBISS㸸࢔࢖ࣅࢫ㸧࡟ࡼࡿ⬻ MRI ⏬ീࢹ࣮
ࢱࡢရ㉁ホ౯ཬࡧ⟶⌮ࢩࢫࢸ࣒ࡢᵓ⠏ࢆ⾜ࡗ࡚࠸ࡿ㸬ᅜ㝿ⓗ࡞⬻⚄⤒⏬ീࡢᕧ኱ࢥࣥࢯ࣮ࢩ࢔
࣒࡛࠶ࡿ ENIGMA ࡜ࡢඹྠ◊✲ࡶᘬࡁ⥆ࡁ⾜ࡗ࡚࠸ࡿ㸬⤫ྜኻㄪ⑕࡟࠾࠸࡚೺ᖖ⪅ࡼࡾయ✚ࡀ኱ࡁ࠸ࡇ࡜ࡀ▱ࡽࢀ࡚࠸ࡿῐ⵬⌫య✚ࡀ⤫ྜኻㄪ⑕ᝈ⪅ࡢ㝧ᛶ⑕≧࡜ṇࡢ┦㛵ࡀ࠶ࡿࡇ࡜
ࢆሗ࿌ࡋࡓ㸦ᶫᮏ㸪୕ᾆ㸪ᐑᒣ㸪ᯇᮏ㸪Ito et al㸪Psychiatry Clin Neurosci㸪2022㸧㸬ࡇࢀࡽࡢ◊✲࡟ࡼࡾ㸪BPCNPNPPP4 Ꮫ఍ྜྠᖺ఍ඃ⚽₇㢟Ⓨ⾲㈹ࢆᯇᮏᐊ㛗ࡀཷ㈹ࡋ㸪௒ᖺᗘࡣ 3⦅ࡢㄽᩥᡂᯝࡀ࠶ࡗࡓ㸬̿ 80 ̿                   ϩ  ◊ ✲ ά ື ≧ ἣ                    㸧 ⢭⚄⑌ᝈࡢ║⌫㐠ື◊✲㸦୕ᾆ㸪ᯇᮏ㸪ᶫᮏ㸧⢭⚄⑌ᝈࡢ║⌫㐠ື◊✲ࡣ㸪኱㜰኱Ꮫ㸦⸨ᮏ㸪ᒣ᳃㸪Ᏻ⏣ᐈဨ◊✲ဨ㸧㸪ྡྂᒇ኱Ꮫ㸦ᑿᓮᐈဨ◊✲ဨ㸧㸪஑ᕞ኱Ꮫ㸦㨣ሯᐈဨ◊✲ဨ㸧㸪ᮾி኱Ꮫ㸪ዉⰋ་⛉኱Ꮫ㸦∾அẁᐈဨ◊✲ဨ㸧㸪໭ᾏ㐨኱Ꮫ㸦ᶫᮏ┤ᶞ㸪ྜྷ⏣㸪ᒸ⏣ᐈဨ◊✲ဨ㸧㸪ᒱ㜧኱Ꮫ㸦኱஭ᐈဨ◊✲ဨ㸧㸪ᚨᓥ኱Ꮫ㸦἟⏣ᐈဨ◊✲ဨ㸧㸪ி㒔኱Ꮫ㸦ᐑ⏣ᐈဨ◊✲ဨ㸧㸪⏕⌮Ꮫ◊✲ᡤ㸦⚟Ọᐈဨ◊✲ဨ㸧࡞࡝࡝ࡢከ᪋タඹྠ◊✲࡟࡚⾜ࡗ࡚࠸ࡿ㸬⤫ྜኻㄪ⑕ࢆ୰ᚰ࡟ࣇ࣮ࣜࣅ࣮ࣗ࢖ࣥࢢㄢ㢟㸪⁥ືᛶ㏣㊧║⌫㐠ືㄢ㢟㸪ὀどㄢ㢟࡞࡝࠿ࡽᚓࡽࢀࡓ║⌫㐠ືࡢ≉ᚩ㸪࠾ࡼࡧ║⌫㐠ື␗ᖖࢆ♧ࡍ║⌫㐠ືࢫࢥ࢔ࡢ
ゎᯒࡸ㸪║⌫㐠ືࡢᇶ♏◊✲࡞࡝ࢆ⾜ࡗࡓ㸬⤫ྜኻㄪ⑕ᝈ⪅ࡢどぬⓗὀព࡟೺ᖖ⪅࡜␗࡞ࡿᛶ㉁ࡀぢࡽࢀࡿࡇ࡜㸪㟋㛗㢮ࣔࢹࣝࡀ⤫ྜኻㄪ⑕ᵝࡢ║⌫㐠ື␗ᖖࢆ♧ࡍࡇ࡜➼ࡢᡂᯝࡀᚓࡽࢀ
ࡓ㸦ᶫᮏ㸪Polyakova et al㸪Front Neurosci㸪2022㸧
㸬ࡉࡽ࡟㸪᪥ᮏ་⒪◊✲㛤Ⓨᶵᵓ㸦AMED㸧་ᕤ㐃ᦠ࣭ேᕤ▱⬟ᐇ⿦◊✲஦ᴗ㸦◊✲ㄢ㢟㸸AI ᢏ⾡ࢆά⏝ࡋࡓ⤫ྜኻㄪ⑕ࡢ᪩ᮇデ᩿་⒪ᶵჾࣉࣟࢢ࣒ࣛࡢ㛤Ⓨ㸧ࡢᨭ᥼ࡢࡶ࡜㸪║⌫㐠ື࡜ㄆ▱ᶵ⬟ࢆ⏝࠸ࡓ⤫ྜኻㄪ⑕ࡢデ᩿࣐࣮࣮࢝
ࡢ♫఍ᐇ⿦໬ࢆ௻ᴗ࡜㸪࢔࢝ࢹ࣑࢔ࡢ 9 ་⒪ᶵ㛵ࡢඹྠ◊✲࡟࡚᥎㐍ࡋ࡚࠸ࡿ㸬║⌫㐠ື࡜ㄆ▱ᶵ⬟ࡢ⤌ྜࡏࡀ⤫ྜኻㄪ⑕ࡢⰋ࠸デ᩿࣐࣮࣮࢝࡞ࡾᚓࡿࡇ࡜➼ࡢᡂᯝࡀᚓࡽࢀࡓ㸬ࡲࡓ㸪་⒪⌧ሙ࡛ᐇ᪋ྍ⬟࡞ࢱࣈࣞࢵࢺᶵჾ࡟࡚⡆౽࡟ᐃ࡛ࡁࡿ་⒪ᶵჾࣉࣟࢢ࣒ࣛ㛤Ⓨࢆ㐍ࡵ㸪ࢱࣈࣞࢵࢺᐇ⿦ࢆ⾜࠸㸪ᐇ㝿࡟೺ᖖ⪅ࡸ⤫ྜኻㄪ⑕ᝈ⪅࡛ᐃࢆ⾜ࡗࡓ㸬௒ᚋ㸪ྲྀᚓࡋࡓࢹ࣮ࢱ

ࢆࡶ࡜࡟᳨ᰝᶵჾ࡜ࡋ࡚ࡢ᏶ᡂᗘࢆ㧗ࡵ㸪≉ᐃ⮫ᗋ◊✲࡟㐍ࡵ࡚࠸ࡃணᐃ࡛࠶ࡿ㸬㸧 ㄆ▱♫఍ᶵ⬟ࣉࣟࢪ࢙ࢡࢺ㸦ᶫᮏ㸪ᯇᮏ㸪୕ᾆ㸪ఀ⸨㸧ᗈࡃデ⒪࡛౑࠼ࡿࡼ࠺࡞⤫ྜኻㄪ⑕ࡢㄆ▱ᶵ⬟㞀ᐖࡢ⡆౽࡞ᐃἲࢆ㛤Ⓨࡋ㸪2000 ౛⛬ᗘࡢࢹ࣮ࢱࢆ COCORO ࡟࡚㞟✚ࡋ࡚ゎᯒࡋ㸪ᬑཬࡢࡓࡵྛᆅ࡛ㅮ⩦఍࡞࡝ࢆ⾜ࡗ࡚࠸ࡿ㸬ㄆ▱ᶵ⬟㞀ᐖࡣ㸪⡆␎∧ WAIS ࡛ᐃࡍࡿ᥎ᐃ▱⬟࡜ Japanese Adult Reading Test㸦JART㸧࡛ᐃࡍࡿ᥎ᐃ⑓๓▱⬟ࡢᕪ࡟࡚⟬ฟࡋࡓࡶࡢ࡛࠶ࡿ㸬 2023 ᖺ 3 ᭶ࡢ➨ 17 ᅇ᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍࡛㸪⤫ྜኻㄪ⑕ࡢㄆ▱♫఍ᶵ⬟㞀ᐖࡢ⡆᫆࡞ᐃἲࡢ࣮࣡ࢡࢩࣙࢵࣉࢆඣ❺࣭ண㜵⢭⚄་Ꮫ◊✲㒊ࡢఫྜྷ㒊㛗࡜ඹ࡟⾜ࡗࡓ㸬⤫ྜኻㄪ⑕ࡔࡅ࡛࡞ࡃ㸪཮ᴟᛶ㞀ᐖ㸪኱࠺ࡘ⑓ᛶ㞀ᐖ㸪⮬㛢ࢫ࣌ࢡࢺ࣒ࣛ⑕ࢆࡲ࡜ࡵ࡚㸪ㄆ▱ᶵ⬟㞀ᐖ࡜㐌ᙜࡓࡾࡢᑵປ᫬㛫ࢆ⏝࠸࡚ࢹ࣮ࢱ㥑ືᆺ࡟ศ㢮ࡍࡿ࡜㸪㸲ࡘࡢࢡࣛࢫࢱ࣮࡟ศ㢮ࡉࢀ㸪ࡍ࡭࡚ࡢデ᩿ࡀࢡࣛࢫࢱ࣮㛫࡛୙ᆒ୍࡟ศᕸࡋ࡚࠸
ࡿࡇ࡜ࡀ♧ࡉࢀࡓ㸬ࡇࡢ⤖ᯝࡣ㸪⢭⚄㞀ᐖ⪅ࡢᶵ⬟ᅇ᚟ࢆᨭ᥼ࡍࡿࡓࡵࡢデ᩿≉␗ⓗ࡞ᡓ␎ࡢ㔜せᛶࢆ♧၀ࡋ࡚࠸ࡿ㸦ᶫᮏ㸪ᯇᮏ㸪୕ᾆ㸪Sumiyoshi et al㸪BJPsych Open㸪2022㸧㸬㸧 ⢭⚄⑌ᝈࡢࢤࣀ࣒࣭⏕యヨᩱ◊✲㸦ᶫᮏ㸪ᯇᮏ㸪୕ᾆ㸧⢭⚄⑌ᝈࡢࢤࣀ࣒࣭⏕యヨᩱ◊✲ࡣ㸪ᅜෆ࡟࠾࠸࡚ࡣ኱㜰኱Ꮫ㸦⸨ᮏ㸪ᒣ᳃㸪Ᏻ⏣㸪ᶫᮏ ᆒᐈဨ◊✲ဨ㸧㸪ྡྂᒇ኱Ꮫ㸦ᑿᓮᐈဨ◊✲ဨ㸧㸪ᮾி㎰ᴗ኱Ꮫ㸦୰⃝ᐈဨ◊✲ဨ㸧㸪ᮾி኱Ꮫ㸦⳥ᆅᐈဨ◊✲ဨ㸧㸪ᚨᓥ኱Ꮫ㸦἟⏣ᐈဨ◊✲ဨ㸧㸪ᒱ㜧኱Ꮫ㸦኱஭ᐈဨ◊✲ဨ㸧㸪ዉⰋ་⛉኱Ꮫ㸦∾அẁᐈဨ◊✲ဨ㸧㸪ᮾி㒔་Ꮫ◊✲ᡤ㸦᪂஭ᐈဨ◊✲ဨ㸧㸪⚟ᓥ┴❧་⛉኱Ꮫ࡞࡝࡜ࡢඹྠ◊✲㸪ࡑࡋ࡚ᅜእ࡟࠾࠸࡚ࡣ཮ᴟᛶ㞀ᐖ࡟࠾ࡅࡿࣜࢳ࣒࢘ࡢ἞⒪཯ᛂᛶࡢ㑇ఏᏛ◊✲ࡢࢥࣥࢯ࣮ࢩ
࢔࣒࡛࠶ࡿ ConLiGen ࡸ ENIGMA ࡜ࡢඹྠ◊✲ࢆ୰ᚰ࡟⾜ࡗ࡚࠸ࡿ㸬௒ᖺᗘࡣྡྂᒇ኱Ꮫࡢ
⢭⚄⑌ᝈࡢࢥࣆ࣮ᩘከᆺ㸦copy number variation㸸CNV㸧ࡢ㑇ఏᏛⓗ◊✲ࡢ 3 ⦅ࢆྵࡴࢤࣀ
࣒◊✲ࡀ 5 ⦅ࡢ◊✲ᡂᯝࡀᚓࡽࢀࡓ㸬㸧 ⢭⚄⑌ᝈࡢศᏊ࣓࢝ࢽࢬ࣒◊✲㸦ᶫᮏ㸪ᯇᮏ㸧ᮾி㎰ᴗ኱Ꮫ㸦୰⃝ᐈဨ◊✲ဨ㸧࡜ᮾி኱Ꮫ㸦⳥ᆅᐈဨ◊✲ဨ㸧࡜ࡢඹྠ◊✲࡟࡚㸪ᘬࡁ⥆
ࡁ᪥ᮏ་⒪◊✲㛤Ⓨᶵᵓ㸦AMED㸧⬻࡜ࡇࡇࢁࡢ◊✲᥎㐍ࣉࣟࢢ࣒ࣛ⢭⚄࣭⚄⤒⑌ᝈ࣓࢝ࢽࢬ
࣒ゎ᫂ࣉࣟࢪ࢙ࢡࢺ㸦◊✲ㄢ㢟㸸iPS ⣽⬊ᢏ⾡࡜ࢹ࣮ࢱ⛉Ꮫࢆ⼥ྜࡋࡓ⢭⚄⑌ᝈᶓ᩿ⓗ࡞཮᪉ྥࢺࣛࣥࢫ࣮ࣞࢩࣙࢼࣝ◊✲㸧ࢆ⾜ࡗ࡚࠸ࡿ㸬⤫ྜኻㄪ⑕࡟ㄆࡵࡽࢀࡿ 3q29 Ḟኻࡸ⮬㛢ࢫ࣌ࢡࢺ࣒ࣛ⑕࡛ㄆࡵࡽࢀࡿ POGZ ኚ␗ࡢ iPS ⣽⬊࡟࠾ࡅࡿᶵ⬟ゎᯒࢆ⾜࠸㸪ᚎࠎ࡟ᡂᯝࡀᚓࡽ

̿ 81 ̿                    ⢭⚄ಖ೺◊✲ᡤᖺሗ ➨36ྕ                   ࢀ࡚࠸ࡿ㸬⚄⤒◊✲ᡤᚤ⣽ᵓ㐀◊✲㒊㸦୍ᡞ㒊㛗㸸ే௵㸧࡜⮬㛢ࢫ࣌ࢡࢺ࣒ࣛ⑕࡟㛵ࡍࡿඹྠ◊✲ࢆᘬࡁ⥆ࡁ⾜ࡗ࡚࠸ࡿ㸬㸧 ྖἲ⢭⚄་Ꮫ㡿ᇦࡢ⏕≀Ꮫⓗ◊✲㸦᯽ᮌ㸪➉⏣㸪୕ᾆ㸪ᯇᮏ㸪ᶫᮏ㸧ᭀຊࡢ᪤ ࡢ࠶ࡿ⤫ྜኻㄪ⑕⩌㸪ᭀຊࡢ᪤ ࡢ࡞࠸⤫ྜኻㄪ⑕⩌㸪೺ᖖ⪅ࢹ࣮ࢱ 1600 ౛௨
ୖࢆ COCORO ࢹ࣮ࢱ࣮࣋ࢫ࠿ࡽᢳฟࡋ㸪⬻⏬ീࡸ║⌫㐠ື࡜ࡢ㛵㐃ࢆ᳨ウࡋ࡚࠸ࡿ㸬㹀㸬⢭⚄⛉་⒪ࡢᬑཬ࣭ᆒ࡚ࢇ໬࡟㛵ࡍࡿ◊✲㸧 ⢭⚄⛉἞⒪࢞࢖ࢻࣛ࢖ࣥࡢᬑཬ࣭ᩍ⫱᳨࣭ドάື㸸(*8,'( ࣉࣟࢪ࢙ࢡࢺ㸦㛗㇂ᕝ㸪ஂಖ⏣㸪బ⸨㸪᯽ᮌ㸪୕ᾆ㸪ᯇᮏ㸪ᶫᮏ㸧
EGUIDE ࣉࣟࢪ࢙ࢡࢺࡣ㸪⢭⚄⛉་࡟ᑐࡋ࡚࢞࢖ࢻࣛ࢖ࣥࡢᩍ⫱ࡢㅮ⩦ࢆ⾜࠸㸪࢞࢖ࢻࣛ࢖
ࣥࡢຠᯝࢆ᳨ドࡍࡿ♫఍ᐇド◊✲࡛࠶ࡿ㸬EGUIDE ࣉࣟࢪ࢙ࢡࢺࡢ୺࡞࣓ࣥࣂ࣮࡛࠶ࡿᮥᯘ
኱Ꮫ㸦Ώ㑔ᐈဨ◊✲ဨ㸧㸪໭㔛኱Ꮫ㸦✄⏣ᐈဨ◊✲ဨ㸧㸪⋊༠་⛉኱Ꮫ㸦ྂ㒆ᐈဨ◊✲ဨ㸧㸪රᗜ་⛉኱Ꮫ㸦ᒣ⏣ᐈဨ◊✲ဨ㸧㸪⚟ᒸ኱Ꮫ㸦ᇼᐈဨ◊✲ဨ㸧࡞࡝㸪24 ྡࡢᐈဨ◊✲ဨ࡜ඹ࡟ඹྠ
◊✲ࢆᐇ᪋ࡋ࡚࠸ࡿ㸬ᑐ㇟࡜ࡍࡿ࢞࢖ࢻࣛ࢖ࣥࡣ㸪⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻࣛ࢖ࣥ࡜࠺ࡘ⑓
἞⒪࢞࢖ࢻࣛ࢖࡛ࣥ࠶ࡾ㸪᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍㸪᪥ᮏ࠺ࡘ⑓Ꮫ఍㸪᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍㸪᪥ᮏ⢭⚄⚄⤒Ꮫ఍ࡢࣂࢵࢡ࢔ࢵࣉࢆཷࡅ࡚⾜ࡗ࡚࠸ࡿ㸬2016 ᖺ࡟㛤ጞࡋࡓ EGUIDE ࣉࣟࢪ࢙ࢡࢺࡣ㸪ᮏᖺᗘ 45 ኱Ꮫ 282 ་⒪ᶵ㛵ࡀཧຍࡍࡿᕧ኱࡞ࣉࣟࢪ࢙ࢡࢺ࡟࡞ࡾ㸪ẖᖺ 10 ᅇ௨ୖࡢㅮ⩦఍ࢆ඲ᅜ࡛⾜࠸㸪ᘏ࡭ 3500 ྡ௨ୖࡢ⢭⚄⛉་ࡀㅮ⩦ࢆཷㅮࡋࡓ㸬EGUIDE ࣉࣟࢪ࢙ࢡࢺ࡟࠾ࡅࡿ᳨ドάືࡣ㸪ㅮ⩦ཷㅮ┤ᚋࡢ࢞࢖ࢻࣛ࢖ࣥࡢ⌮ゎᗘࡢྥୖ㸪ࡑࡢᚋࡢ࢞࢖ࢻࣛ࢖
ࣥࢆ㑂Ᏺࡋࡓ἞⒪⾜ືㄪᰝ࡟࠾ࡅࡿᐇ㊶ᗘࡢྥୖ㸪ฎ᪉⾜ືࢆデ⒪ࡢ㉁㸦Quality Indicator: QI㸧࡜࠸࠺ᙧ࡛ᐃࡋ㸪౛࠼ࡤ⤫ྜኻㄪ⑕ᝈ⪅ࡢ㏥㝔᫬ࡢᢠ⢭⚄⑓⸆༢๣἞⒪⋡࡜࠸࠺ࡼ࠺࡞ QI

ࢆタᐃࡋ㸪⤒᫬ⓗ࡟ᐃࡍࡿࡇ࡜࡟ࡼࡾ㸪ㅮ⩦ࡢຠᯝࡢ᭷↓࡟ࡘ࠸࡚ࡢ᳨ウࢆ⾜ࡗࡓ㸬ࡓࡗࡓ୍᪥ࡢㅮ⩦ࢆཷࡅࡿࡇ࡜࡟ࡼࡾ⤫ྜኻㄪ⑕࡜࠺ࡘ⑓ࡢ୧᪉ࡢ࢞࢖ࢻࣛ࢖ࣥ࡟ᑐࡍࡿ⌮ゎᗘࡀ㢧ⴭ࡟ྥୖࡍࡿࡇ࡜ࢆ᫖ᖺᗘㄽᩥሗ࿌ࡋ㸪ࡑࡢ࢞࢖ࢻࣛ࢖ࣥࡢᐇ㊶ᗘࡶ㢧ⴭ࡟ྥୖࡋ㸪ࡑࢀࡀ
2 ᖺ㛫ᣢ⥆ࡍࡿࡇ࡜ࢆ♧ࡋࡓ㸦㛗㇂ᕝ㸪ᯇᮏ㸪୕ᾆ, ᶫᮏ㸪Yamada et al㸪BJPsych Open㸪
2022㸧. ࡲࡓ㸪ࡇࡢㅮ⩦ࢆཷㅮࡋࡓཷㅮ⪅ࡢ‶㊊ᗘࡣ㠀ᖖ࡟㧗࠸ࡇ࡜ࡶሗ࿌ࡋࡓ㸦㛗㇂ᕝ㸪ᯇᮏ㸪୕ᾆ, ᶫᮏ㸪Ogasawara et al㸪Neuropsychopharmacol Rep㸪2022㸧㸬᭦࡟㸪Corvid ឤᰁ⑕ࡢᙳ㡪࡛㸪ᑐ㠃ㅮ⩦࠿ࡽ࢙࢘ࣈㅮ⩦࡟ษࡾ᭰࠼ࡓࡀ㸪࢙࢘ࣈㅮ⩦࡟࠾࠸࡚ࡶᑐ㠃ㅮ⩦࡜ྠᵝ࡟⌮ゎᗘཬࡧ‶㊊ᗘࡀᚓࡽࢀࡿࡇ࡜ࢆ♧ࡋࡓ㸦㛗㇂ᕝ㸪ᯇᮏ㸪୕ᾆ, ᶫᮏ㸪Iida et al㸪
Neuropsychopharmacol Rep㸪2022㸧
㸬ࢡࣟࢨࣆࣥࡣ἞⒪᢬ᢠᛶ⤫ྜኻㄪ⑕࡟၏୍㐺ᛂࡢ࠶ࡿᢠ⢭⚄⑓⸆࡛࠶ࡾ㸪ୡ⏺୰ࡢ࢞࢖ࢻࣛ
࢖࡛ࣥࡶ἞⒪᢬ᢠᛶ⤫ྜኻㄪ⑕㸻ࢡࣟࢨࣆࣥ἞⒪࡜ࡉࢀ࡚࠸ࡿ㸬ࡋ࠿ࡋ㸪᪥ᮏ࡛ࡢࢡࣟࢨࣆࣥ἞⒪⋡ࡣㅖእᅜࡢᴫࡡ 1/10 ⛬ᗘ࡛࠶ࡾ㸪ᬑཬࡀᚲせ࡜ࡉࢀ࡚࠸ࡿ㸬⤫ྜኻㄪ⑕ࡢᢠ⢭⚄⑓⸆༢๣἞⒪⋡ࡣ඲ᅜᖹᆒࡀ⣙ 57㸣࡛࠶ࡿࡀ㸪ࢡࣟࢨࣆࣥࢆฎ᪉ࡉࢀ࡚࠸ࡿ἞⒪᢬ᢠᛶ⤫ྜኻㄪ⑕࡛ࡣ⣙ 90㸣࡜࡞ࡗ࡚࠾ࡾ㸪௚ࡢྥ⢭⚄⸆ࡢే⏝ࡶᑡ࡞ࡃ㸪἞⒪᢬ᢠᛶ⤫ྜኻㄪ⑕ࡢ἞⒪࡜ࡋ࡚
ࢡࣟࢨࣆࣥࢆ⏝࠸ࡿࡇ࡜ࡀࡼࡾ㐺ษ࡞἞⒪࡟ࡘ࡞ࡀࡿྍ⬟ᛶࡀ♧၀ࡉࢀࡓ㸦㛗㇂ᕝ㸪ᯇᮏ㸪୕ᾆ, ᶫᮏ㸪Ochi et al㸪Int J Neuropsychopharmacol㸪2022㸧. ᢠ⢭⚄⑓⸆ࡢ㗹యእ㊰⣔๪స⏝࡟⏝࠸ࡽࢀࡿࡇ࡜ࡀ࠶ࡿᢠࢥࣜࣥ⸆ࡢ㏥㝔᫬ࡢฎ᪉⋡ࡣ඲ᅜ࡛⣙ 30㸣࡜࡞ࡗ࡚࠾ࡾㅖእᅜࡼ
ࡾ㧗࠸ࡔࡅ࡛࡞ࡃ㸪0㹼67㸣࡜⑓㝔࡟ࡼࡾࡤࡽࡘࡁࡀከ࠿ࡗࡓ㸦㛗㇂ᕝ㸪ᯇᮏ㸪୕ᾆ, ᶫᮏ㸪Hori
et al㸪Front Psychiatry, section Psychopharmacology㸪2022㸧㸬ධ㝔๓࡟ᢠࢥࣜࣥ⸆ࢆฎ᪉ࡉ
ࢀ࡚࠸࡚㏥㝔᫬࡟୰Ṇࡋ࡚࠸ࡓᝈ⪅࡟࠾࠸࡚㸪㏥㝔᫬࡟ᢠ⢭⚄⑓⸆༢๣἞⒪⋡ࡀ㧗ࡃ㸪➨஧ୡ௦ᢠ⢭⚄⑓⸆ࡢฎ᪉๭ྜࡀ㧗࠸ࡇ࡜ࡀぢ࠸ࡔࡉࢀࡓ㸦㛗㇂ᕝ㸪ᯇᮏ㸪୕ᾆ, ᶫᮏ㸪Okada et al㸪
J Clin Psychopharmacol㸪2022㸧
㸬⤫ྜኻㄪ⑕࡜࠺ࡘ⑓୧᪉࡟࠾࠸࡚㸪㟁Ẽࡅ࠸ࢀࢇ⒪ἲࢆཷࡅࡓᝈ⪅࡛ࡣ㏥㝔᫬ࡢᢠ୙Ᏻ⸆࣭
╧╀⸆ࡢ౑⏝⋡ࡀప࠸ࡇ࡜࡞࡝ࢆぢฟࡋࡓ㸦㛗㇂ᕝ㸪ᯇᮏ㸪୕ᾆ, ᶫᮏ㸪Tsuboi et al㸪Psychiatry̿ 82 ̿                   ϩ  ◊ ✲ ά ື ≧ ἣ                    Clin Neurosci㸪2023㸧
㸬ࡲࡓ㸪㡻⏝⸆ࡣࡋࡤࡋࡤ⮫ᗋሙ㠃࡛⏝࠸ࡽࢀ࡚࠸ࡿࡀ㸪᭷⏝ᛶࡢ࢚ࣅࢹࣥࢫ࡟ஈࡋࡃ⤫ྜኻㄪ⑕࡟࠾࠸࡚ࡶ࠺ࡘ⑓࡟࠾࠸࡚ࡶ࢞࢖ࢻࣛ࢖࡛ࣥ᥎ዡࡉࢀ࡚࠸࡞࠸㸬ࡇࡢᒡ⏝⸆ࡢᐇែࢆᢕᥱࡋ㸪ྥ⢭⚄⸆ࡢᒡ⏝ฎ᪉ࡀከ࠸ࡇ࡜࡜ࡑࡢྥ⢭⚄⸆ࡢే⏝ࡢከࡉࡀ┦㛵ࡍࡿࡇ࡜ࢆぢฟࡋࡓ㸦㛗㇂ᕝ㸪ᯇᮏ㸪୕ᾆ, ᶫᮏ㸪Kyou et al㸪Ann Gen Psychiatry㸪2022㸧
㸬ࡇࡢࡇ࡜ࡣ㸪ᒡ⏝ฎ᪉࠿ࡽే⏝ฎ᪉࡟ࡘ࡞ࡀࡗ࡚࠸ࡃྍ⬟ᛶࢆ♧၀ࡋ࡚࠸ࡿ㸬࠺ࡘ⑓἞⒪࢞࢖ࢻࣛ࢖࡛ࣥࡣ㔜⑕ᗘ࡟ࡼࡗ࡚᥎ዡࡍࡿ἞⒪ࡀ␗࡞ࡿࡀ㸪௒ࡲ࡛࡟㔜⑕ᗘࢆ࡝ࢀࡄࡽ࠸ุ᩿ࡋ࡚࠸ࡿ࠿࡜࠸࠺ᐇែㄪᰝࡣ࡞࠿ࡗࡓ㸬EGUIDE ࣉࣟࢪ࢙ࢡࢺ࡛ࡣ㸪඲ᅜࡢ㔜⑕ᗘࡢグ㍕⋡ࡀ⣙ 57㸣࡛࠶ࡾ㸪⑓㝔ࡈ࡜࡟ 0㹼100%࡜኱ࡁࡃࡤࡽࡘ࠸࡚࠾ࡾ㸪ᆒ࡚ࢇ໬ࡀᚲせ࡞ࡇ࡜ࢆ♧ࡋࡓ㸦㛗㇂ᕝ㸪ᯇᮏ㸪୕ᾆ, ᶫᮏ㸪Muraoka et al㸪Asian Jornal of psychiatry㸪2022㸧.
ୖグࡢࡼ࠺࡟᪥ᮏࡢ⢭⚄⛉デ⒪ᐇែㄪᰝ࡛ࡣ㸪඲ᅜࡢᖹᆒ್ࡸ⑓㝔ࡈ࡜ࡢᖹᆒ್ࢆㄪ࡭࡚㸪ᆒ࡚ࢇ໬ࡢᚲせᛶࢆぢฟࡋࡓ㸬୍᪉࡛㸪୍ே୍ேࡢᝈ⪅࡟ࡘ࠸࡚ࡣ㸪࡝ࢀࡄࡽ࠸࢞࢖ࢻࣛ࢖ࣥ
࡟‽ᣐࡋࡓ἞⒪ࢆ⾜ࡗ࡚࠸ࡿ࠿ࢆホ౯ࡍࡿ᪉ἲࡣ࡞ࡃ㸪࢞࢖ࢻࣛࣥࡢ඲࡚ࡢ⮫ᗋ␲ၥࢆ⥙⨶ࡋ࡚ゎ㔘ࢆࡋࡓୖ࡛㸪ᝈ⪅࡟ㄝ᫂ࡋ࡚ඹྠពᛮỴᐃࢆ⾜࠺ࡇ࡜࡜࡞ࡿ㸬⢭⚄⛉་ࡣࡶࡕࢁࢇ࢞࢖
ࢻࣛ࢖ࣥࢆ㋃ࡲ࠼ࡓ㐺ษ࡞ゎ㔘ࢆ࡛ࡁࡿࡼ࠺࡟⢭㐍ࡍ࡭ࡁ࡛࠶ࡿࡀ㸪ᝈ⪅ࡀࡑࡢ඲࡚ࢆྠࡌࡼ
࠺࡟⌮ゎࡍࡿࡇ࡜ࡣᅔ㞴࡛࠶ࡿ㸬ࡑࡇ࡛㸪ᝈ⪅ࡀࡼࡾ⌮ゎࡋࡸࡍࡃ࡞ࡿࡼ࠺࡟㸪ฎ᪉ࡀ࡝ࢀࡄ
ࡽ࠸࢞࢖ࢻࣛ࢖ࣥ࡟㐺ྜࡋ࡚࠸ࡿ࠿࡜࠸࠺ᣦᶆ㸦Individual fitness score: IFS㸧ࢆసᡂࡋࡓ㸦㛗㇂ᕝ㸪ᯇᮏ㸪୕ᾆ, ᶫᮏ㸪Inada et al㸪Neuropsychopharmacol Rep㸪2022; 㛗㇂ᕝ㸪ᯇᮏ㸪୕ᾆ, ᶫᮏ㸪Fukumoto et al㸪Neuropsychopharmacol Rep㸪2022㸧
㸬ࡇࡢ IFS ࡣ㸪᭱ࡶ࢞࢖ࢻ
ࣛ࢖ࣥ࡟㐺ྜࡋ࡚࠸ࡿฎ᪉ࢆ 100 Ⅼ࡜ࡋ㸪࢞࢖ࢻࣛ࢖ࣥ࡟່࡚ࡵࡽࢀ࡚࠸࡞࠸἞⒪ࢆ⾜࠺࡜ῶⅬࢆ⾜࠸㸪᭱పⅬࢆ 0 Ⅼ࡜ࡍࡿࡼ࠺࡟ࡋ࡚࠸ࡿ㸬ࡇࡢ㝿࡟᭱ࡶ㔜せ࡞ࡇ࡜ࡣ㸪⤫ྜኻㄪ⑕࡟࠾
࠸࡚ࡶ࠺ࡘ⑓࡟࠾࠸࡚ࡶ㸪ୗ఩デ᩿㸦⤫ྜኻㄪ⑕㸸἞⒪᢬ᢠᛶ㸪࠺ࡘ⑓㸸㍍⑕/୰➼⑕࣭㔜⑕/⢭⚄⑓ᛶ㸧࡟ࡼࡗ࡚᥎ዡࡉࢀࡿ἞⒪ࡀ␗࡞ࡿࡓࡵ㸪᭱ࡶ࢞࢖ࢻࣛ࢖ࣥ࡟㐺ྜࡋ࡚࠸ࡿ἞⒪ࡀ␗࡞
ࡿ࡜࠸࠺ࡇ࡜࡛࠶ࡿ㸬౛࠼ࡤ⤫ྜኻㄪ⑕࡟࠾࠸࡚ࡣ➨஧ୡ௦ᢠ⢭⚄⑓⸆༢๣἞⒪ࢆ⾜࠺࡜ 100
Ⅼ࡛࠶ࡾ㸪ᢠ⢭⚄⑓⸆ࡸྥ⢭⚄⸆ࡢే⏝ࢆ⾜࠺࡜୍๣࠶ࡓࡾ 15㹼80 ⅬࢆῶⅬࡉࢀࡿ㸬἞⒪᢬
ᢠᛶ⤫ྜኻㄪ⑕࡟࠾࠸࡚ࡣ㸪ࢡࣟࢨࣆࣥ἞⒪ࢆ⾜࠺࡜ 100 Ⅼ࡜࡞ࡾ㸪ࢡࣟࢨࣆࣥ἞⒪ࢆ⾜ࡗ࡚࠸࡞ࡅࢀࡤ 60 ⅬࡢῶⅬ࡜࡞ࡿ㸬ࡇࡢࡼ࠺࡞ IFS ࢆ⏝࠸ࡓデ⒪ሙ㠃࡜ࡋ࡚㸪⤫ྜኻㄪ⑕ᝈ⪅ࡀ୙╀ࢆッ࠼╧╀⸆ࡢฎ᪉ࢆᕼᮃࡋࡓ㝿࡟㸪IFS ࡀ 80 Ⅼ࠿ࡽ 65 Ⅼ࡟࡞ࡿࡇ࡜ࢆㄝ᫂ࡋ㸪࢞࢖ࢻࣛ࢖࡛ࣥࡣ୙╀ࡢሙྜ࡟ࡣࡑࡢཎᅉࢆ⢭ᰝࡍࡿࡇ࡜࡟࡞ࡗ࡚࠸ࡿࡇ࡜࠿ࡽ㸪ၥデࢆ⾜ࡗ࡚㸪୙╀ࡢ⌮⏤ࡣᗁ⫈ࡢᝏ໬࡜ࢃ࠿ࡾ㸪ᢠ⢭⚄⑓⸆ࡢ⏝㔞ࡀ୙༑ศ࡞ࡢ࡛ቑ㔞ࡍࡿ࡜࠸࠺ᑐᛂࢆ⾜࠺࡜࠸࠺ࡼ࠺࡞ὶࢀ࡜࡞ࡿ㸬ᝈ⪅࡟࡜ࡗ࡚ࡣ㸪Ⅼᩘ࡟࡚⮬㌟ࡢฎ᪉࡜ᶆ‽ⓗ࡞἞⒪࡜ࡢ㐪࠸ࡀ⌮ゎࡋࡸࡍࡃ㸪ᶆ‽ⓗ࡞἞⒪ࢆ⾜࠺ࡇ࡜࡟ࡘ࠸࡚ㄝ᫂ࡍࡿࡇ࡜࡟ࡼࡗ࡚㸪἞⒪࡟ᑐࡍࡿ⌮ゎࢆ῝ࡵࡸࡍࡃ࡞ࡿ࡜⪃࠼ࡽࢀࡿ⏬ᮇⓗ࡞◊✲ᡂᯝ࡛࠶ࡿ㸬ࡇࡢࡼ࠺࡟㸪࢞࢖ࢻࣛ࢖ࣥࡢᬑཬάືࢆ඲ᅜ࡛⾜࠸㸪ㄽᩥᡂᯝࡣ 11 ⦅࡛࠶ࡗࡓ㸬㸧 ⢭⚄⛉἞⒪࢞࢖ࢻࣛ࢖ࣥࡢసᡂ࣭ᨵゞ㸦ᶫᮏ㸧⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻࣛ࢖ࣥࢆᙜ஦⪅࣭ᐙ᪘࣭ᨭ᥼⪅࡞࡝㛵㐃ᅋయࡍ࡭࡚ࢆ⥙⨶ࡋࡓ 80ྡ௨ୖࡢጤဨ࡜ඹྠ࡛ᨵゞࢆ⾜࠸ 2022 ᖺᗘ 5 ᭶࡟බ㛤ࡋࡓ㸬⢭⚄⛉㡿ᇦ࡛ࡣึࡵ࡚ࡢヨࡳ࡛࠶ࡾ㸪௚ࡢデ⒪㡿ᇦ࡟࠾࠸࡚ࡶඛ㐍ⓗ࡞ྲྀࡾ⤌ࡳ࡛࠶ࡿ㸬᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍࡜᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍࠿ࡽࣉࣞࢫ࣮ࣜࣜࢫࢆ⾜࠸㸪་Ꮫ⣔᝟ሗ࣓ࢹ࢕࢔ࢆ୰ᚰ࡟ὀ┠ࢆ㞟ࡵᗈࡃ࢖ࣥ
ࢱ࣮ࢿࢵࢺ➼࡛ྲྀࡾୖࡆࡽࢀࡓ㸬Ϫ㸬♫఍ⓗάື࡟㛵ࡍࡿホ౯ ᕷẸ♫఍࡟ᑐࡍࡿ୍⯡ⓗ࡞㈉⊩࣭ᑓ㛛ᐙྥࡅࡢ⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻࣛ࢖ࣥ 2022 ࡢᙜ஦⪅࣭ᨭ᥼⪅⏝ࡢ⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻ 2022 ࢆసᡂࡋ 2023 ᖺ 2 ᭶࡟බ㛤ࡋࡓ㸬

̿ 83 ̿                    ⢭⚄ಖ೺◊✲ᡤᖺሗ ➨36ྕ                    ᑓ㛛ᩍ⫱㠃࡟࠾ࡅࡿ㈉⊩࣭⤫ྜኻㄪ⑕ࡸ࠺ࡘ⑓࡞࡝ࡢ࢞࢖ࢻࣛ࢖ࣥࡢసᡂࢆ⾜࠸㸪⢭⚄⛉἞⒪࢞࢖ࢻࣛ࢖ࣥࡢᬑཬ࣭ᩍ⫱᳨࣭ドάື࡛࠶ࡿ EGUIDE ࣉࣟࢪ࢙ࢡࢺࡶ඲ᅜᒎ㛤ࡋ࡚࠸ࡿ㸬EGUIDE ࣉࣟࢪ࢙ࢡࢺ࡟࠾࠸࡚
ࡣ㸪⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻࣛ࢖ࣥ࡜࠺ࡘ⑓἞⒪࢞࢖ࢻࣛ࢖ࣥࡢㅮ⩦ࢆ඲ᅜࡢ⢭⚄⛉་ࢆᑐ㇟࡟⾜࠸㸪ࡑࡢ་⒪ᶵ㛵࡟࠾ࡅࡿ἞⒪࡟ᙳ㡪ࢆ୚࠼ࡿ࠿࡝࠺࠿࡟ࡘ࠸࡚ࡢ᳨ウࢆ⾜࠸㸪⢭⚄⛉་⒪ࡢᬑཬ࡜ᩍ⫱࡟ᑐࡍࡿ࢞࢖ࢻࣛ࢖ࣥࡢຠᯝࢆ᳨ドࡋ࡚࠸ࡿ㸬௧࿴ 4 ᖺᗘࡣ㸪⤫ྜኻㄪ⑕⸆
≀἞⒪࢞࢖ࢻࣛ࢖ࣥ࡜࠺ࡘ⑓἞⒪࢞࢖ࢻࣛ࢖ࣥࡢㅮ⩦ࢆ඲ᅜ 14 ࠿ᡤ࡛⾜࠸㸪45 ௨ୖࡢ་⒪ᶵ㛵㸪ᘏ࡭ 538 ྡࡢ⢭⚄⛉་ࡀཧຍࡋࡓ㸦㛗㇂ᕝ㸪ஂಖ⏣㸪బ⸨㸪᯽ᮌ㸪ᶫᮏ㸧㸬࣭㛤Ⓨࡋࡓ⤫ྜኻㄪ⑕ࡢㄆ▱ᶵ⬟㞀ᐖࡢ⡆౽࡞ᐃἲ࡟ࡘ࠸࡚ࡢㅮ⩦఍ࢆ⤫ྜኻㄪ⑕Ꮫ఍࡟࠾

࠸࡚⾜࠸㸪ホ౯ࢩ࣮ࢺࢆ㓄ᕸࡋᬑཬάືࢆ⾜ࡗࡓ㸦ᯇᮏ㸪ఀ⸨㸪ᶫᮏ㸧㸬࣭ᅜ❧኱Ꮫἲே ኱㜰኱Ꮫࡢ་Ꮫ⣔◊✲⛉㸪㐃ྜᑠඣⓎ㐩Ꮫ◊✲⛉࡟࠾࠸࡚ࡣᣍ࡬࠸ᩍᤵ࡜ࡋ࡚㸪ዉⰋ┴❧་⛉኱Ꮫ࡟࠾࠸࡚ࡣ㠀ᖖ໅ㅮᖌ࡜ࡋ࡚㸪⢭⚄་Ꮫ◊✲ࡢᣦᑟࡸ▱ぢࡢᩍᤵࢆ⾜ࡗ࡚࠸ࡿ㸦ᶫᮏ㸧㸬 ⢭◊ࡢ◊ಟࡢ୺ദ࡜༠ຊ
࣭

2022 ᖺᗘᅜ❧⢭⚄࣭⚄⤒་⒪◊✲ࢭࣥࢱ࣮⢭⚄ಖ೺࡟㛵ࡍࡿᢏ⾡◊ಟ࡛➨ 1 ᅇ┠ࡢ࠺ࡘ⑓ࡢᶆ‽἞⒪◊ಟ㸪⤫ྜኻㄪ⑕ࡢᶆ‽἞⒪◊ಟࢆ⾜ࡗࡓ㸦᯽ᮌ㸪㛗㇂ᕝ㸪ᶫᮏ㸧㸬 ಖ೺་⒪⾜ᨻᨻ⟇࡟㛵㐃ࡍࡿ◊✲࣭ㄪᰝ㸪ጤဨ఍➼࡬ࡢ㈉⊩ ࢭࣥࢱ࣮ෆ࡟࠾ࡅࡿ⮫ᗋⓗάື࣭እ᮶デ⒪࡟࠾࠸࡚㸪㐃ᦠ᪂ᝈ㸪⤫ྜኻㄪ⑕እ᮶ࢆࡑࢀࡒࢀ㐌࡟ 1 ᅇࡢ᪂ᝈᯟࡢデᐹཬࡧ㸪෌デࢆ㐌࡟༙᪥⾜ࡗ࡚࠸ࡿ㸬ᑓ㛛࡜ࡋ࡚㸪⤫ྜኻㄪ⑕ཬࡧⓎ㐩㞀ᐖࡢデ⒪ࢆ⾜࠸㸪⑓㝔ෆእ࠿ࡽࡢ
⤂௓ࢆཷࡅ㸪ࢭ࢝ࣥࢻ࢜ࣆࢽ࢜ࣥᑐᛂࡶ⾜ࡗ࡚࠸ࡿ㸦ᶫᮏ㸧㸬 ࡑࡢ௚
ϫ㸬◊✲ᴗ⦼
㸿㸬ห⾜≀
 ཎⴭㄽᩥ


Cearns M, Amare AT, Schubert KO, Thalamuthu A, Frank J, Streit F, Adli M, Akula N,
Akiyama K, Ardau R, Arias B, Aubry JM, Backlund L, Bhattacharjee AK, Bellivier F,
Benabarre A, Bengesser S, Biernacka JM, Birner A, Brichant-Petitjean C, Cervantes P,
Chen HC, Chillotti C, Cichon S, Cruceanu C, Czerski PM, Dalkner N, Dayer A, Degenhardt
F, Zompo MD, DePaulo JR, Etain B, Falkai P, Forstner AJ, Frisen L, Frye MA, Fullerton
JM, Gard S, Garnham JS, Goes FS, Grigoroiu-Serbanescu M, Grof P, Hashimoto R,(117 ྡ୰ 43 ␒┠) Hauser J, Heilbronner U, Herms S, Hoffmann P, Hofmann A, Hou L, Hsu YH,
Jamain S, Jimenez E, Kahn JP, Kassem L, Kuo PH, Kato T, Kelsoe J, Kittel-Schneider S,
Kliwicki S, König B, Kusumi I, Laje G, Landén M, Lavebratt C, Leboyer M, Leckband SG,
Maj M; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium,
Manchia M, Martinsson L, McCarthy MJ, McElroy S, Colom F, Mitjans M, Mondimore FM,
Monteleone P, Nievergelt CM, Nöthen MM, Novák T, O'Donovan C, Ozaki N, Millischer V,
Papiol S, Pfennig A, Pisanu C, Potash JB, Reif A, Reininghaus E, Rouleau GA, Rybakowski
JK, Schalling M, Schofield PR, Schweizer BW, Severino G, Shekhtman T, Shilling PD,
Shimoda K, Simhandl C, Slaney CM, Squassina A, Stamm T, Stopkova P, Tekola-Ayele F,̿ 84 ̿                   ϩ  ◊ ✲ ά ື ≧ ἣ                    

Tortorella A, Turecki G, Veeh J, Vieta E, Witt SH, Roberts G, Zandi PP, Alda M, Bauer M,
McMahon FJ, Mitchell PB, Schulze TG, Rietschel M, Clark SR, Baune BT: Using polygenic
scores and clinical data for bipolar disorder patient stratification and lithium response
prediction: machine learning approach. Br J Psychiatry 220:219-228, 2022.
Yamada H, Motoyama M, Hasegawa N, Miura K, Matsumoto J, Ohi K, Yasui-Furukori N,
Numata S, Takeshima M, Sugiyama N, Nagasawa T, Kubota C, Atake K, Tsuboi T, Ichihashi
K, Hashimoto N, Inagaki T, Takaesu Y, Iga JI, Hori H, Onitsuka T, Komatsu H, Hishimoto
A, Fukumoto K, Fujimoto M, Nakamura T, Nemoto K, Furihata R, Yamamura S, Yamagata
H, Ogasawara K, Katsumoto E, Murata A, Iida H, Ochi S, Makinodan M, Kido M, Kishimoto
T, Yasuda Y, Usami M, Suwa T, Inada K, Watanabe K, Hashimoto R: A dissemination andeducation programme to improve the clinical behaviours of psychiatrists in accordance withtreatment guidelines for schizophrenia and major depressive disorders: the Effectiveness of
Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project.
BJPsych Open 8(3):e83, 2022.



Kubota R, Okubo R, Ikezawa S, Matsui M, Adachi L, Wada A, Fujimaki C, Yamada Y, Saeki
K, Sumiyoshi C, Kikuchi A, Omachi Y, Takeda K, Hashimoto R, Sumiyoshi T, Yoshimura N:
Sex differences in social cognition and association of social cognition and neurocognition inearly course schizophrenia. Front Psychiatry, section Psychopathology 13:867468, 2022.

Hori H, Yasui-Furukori N, Hasegawa N, Iga JI, Ochi S, Ichihashi K, Furihata R, Kyo Y,
Takaesu Y, Tsuboi T< Kodaka F, Onitsuka T, Okada T, Murata A, Kashiwagi H, Iida H,
Hashimoto N, Ohi K, Yamada H, Ogasawara K, Yasuda Y, Muraoka H, Usami M, Numata
S, Takeshima M, Yamagata H, Nagasawa T, Tagata H, Makinodan M, Kido M, Katsumoto
E, Komatsu H, Matsumoto J, Kubota C, Miura K, Hishimoto A, Watanabe K, Inada K,
Kawasaki H, Hashimot R: Prescription of anticholinergic drugs in patients withschizophrenia: analysis of antipsychotic prescription patterns and hospital characteristics.
Front Psychiatry, section Psychopharmacology 13:823826, 2022.

Takahashi T, Tsugawa S, Nakajima S, Plitman E, Chakravarty MM, Masuda F, Wada M,
Kurose S, Ochi R, Matsushita K, Sasabayashi D, Nakamura M, Nishikawa Y, Takayanagi
Y, Nishiyama S, Higuchi Y, Mizukami Y, Furuichi A, Kido M, Hashimoto R, Noguchi K, Fujii
S, Mimura M, Noda Y, Suzuki M: Thalamic and striato-pallidal volumes in schizophrenia
patients and individuals at risk for psychosis: A multi-atlas segmentation study. Schizophr
Res 243:268-275, 2022.



Sumiyoshi C, Ohi K, Fujino H, Yamamori H, Fujimoto M, Yasuda Y, Uno Y, Takahashi J,
Morita K, Katsuki A, Yamamoto M, Okahisa Y, Sata A, Katsumoto E, Koeda M, Hirano Y,
Nakataki M, Matsumoto J, Miura K, Hashimoto N, Makinodan M, Takahashi T, Nemoto K,
Kishimoto T, Suzuki M, Sumiyoshi T, Hashimoto R: Transdiagnostic comparisons ofintellectual abilities and work outcome in patients with mental disorders: multicentre study.
BJ Psych Open 8(4):e98, 2022.

Ogasawara K, Numata S, Hasegawa N, Nakataki M, Makinodan M, Ohi K, Takeshima M,
Tsuboi T, Hashimoto N, Onitsuka T, Muraoka H, Hori H, Ichihashi K, Inagaki T, YasuiFurukori N, Hishimoto A, Sugiyama N, Fukumoto K, Nagasawa T, Matsumoto J, Takaesu
Y, Furihata R, Nemoto K, Nakamura T, Usami M, Miura K, Fujimoto M, Tagata H, Yamada
H, Komatsu H, Ochi S, Atake K, Katsumoto E, Kido M, Kishimoto T, Suwa T, Yamamura S,
Iga JI, Iida H, Inada K, Watanabe K, Hashimoto R: Subjective assessment of participantsin education programs on clinical practice guidelines in the field of psychiatry.
Neuropsychopharmacol Rep 42(2):221-225, 2022.

̿ 85 ̿                    ⢭⚄ಖ೺◊✲ᡤᖺሗ ➨36ྕ                   Demizu Y, Matsumoto J, Yasuda Y, Ito S, Miura K, Yamamori H, Fujimoto M, Hasegawa N,
Ishimaru K, Hashimoto R: Relationship between autistic traits and social functioning in
healthy individuals. Neuropsychopharmacol Rep 42(2):226-229, 2022.



Nawa Y, Kushima I, Aleksic B, Yamamoto M, Kimura H, Banno M, Hashimoto R, Ozaki N:
Treatment-resistant schizophrenia in patients with 3q29 deletion: A case series of four
patients. Psychiatry Clin Neurosci 76(7):338-339, 2022.



Muraoka H, Kodaka F, Hasegawa N, Yasui-Furukori N, Fukumoto K, Kashiwagi H, Tagata
H, Hori H, Atake K, Iida H, Ichihashi K, Furihata R, Tsuboi T, Takeshima M, Komatsu H,
Kubota C, Ochi S, Takaesu Y, Usami M, Nagasawa T, Makinodan M, Nakamura T, Kido M,
Ueda I, Yamagata H, Onitsuka T, Asami T, Hishimoto A, Ogasawara K, Katsumoto E, Miura
K, Matsumoto J, Ohi K, Yamada H, Watanabe K, Inada K, Nishimura K, Hashimoto R:
Characteristics of the treatments for each severity of major depressive disorder: A realworld multi-site study. Asian Jornal of psychiatr 74:103174, 2022.

Kushima I, Nakatochi M, Aleksic B, Okada T, Kimura H, Kato H, Morikawa M, Inada T,
Ishizuka K, Torii Y, Nakamura Y, Tanaka S, Imaeda M, Takahashi N, Yamamoto oM,
Iwamoto K, Nawa Y, Ogawa N, Iritani S, Hayashi Y, Lo T, Otogonbayar G, Furuta S, Iwata
N, Ikeda M, Siato T, Ninomiya K, Okochi T, Hashimoto R, Yamamori H, Yasuda Y, Fujimoto
M, Miura K, Itokawa M, Arai M, MIyashita M, Toriumi K, Ohi K, ShioiriT, Kitaichi K,
Someya T, Watanabe Y, Egawa J, Takahashi T, Suzuki M, Sasaki T, Tochigi M, Nishimura
F, Yamasue H, Kuwabara H, Wakuda T, Kato T, Kanba S, Horikawa H, Usami M, KodairaM, Watanabe K, Yoshikawa T, Toyota T, Yokoyama S, Munesue T, Kimura R, Funabiki Y,
Kosaka H, Jung M, Kasai K, Ikegame T, Jinde S, Numata S, Kinoshita M, Kato T, Kakiuchi
C, Yamakawa K, Suzuki T, Hashimoto N, Ishikawa S, Yamagata B, Nio S, Murai T, Son S,
Kunii Y, Yabe H, Inagaki M, Goto Y, Okumura Y, Ito T, Arioka Y, Mori D, Ozaki N: Crossdisorder analysis of genic and regulatory copy number variations in bipolar disorder,
schizophrenia, and autism spectrum disorder. Biological Psychiatry 92(5):362-374, 2022.

Polyakova Z, Iwase M, Hashimoto R, Yoshida M: The effect of ketamine on eye movement
characteristics during free-viewing of natural images in common marmosets. Front
Neurosci,section Perception Science 16:1012300, 2022.

Ochi S, Tagata H, Hasegawa N, Yasui-Furukori N, Iga JI, Kashiwagi H, Kodaka F, Komatsu
H, Tsuboi T, Tokutani A, Numata S, Ichihashi K, Onitsuka T, Muraoka H, Iida H, Ohi K,
Atake K, Kishimoto T, Hori H, Takaesu Y, Takeshima M, Usami M, Makinodan M,
Hashimoto N, Fujimoto M, Furihata R, Nagasawa T, Yamada H, Matsumoto J, Miura K,
Kido M, Hishimoto A, Ueno SI, Watanabe K, Inada K, Hashimoto R: Clozapine Treatment
Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower
Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide Study. Int
J Neuropsychopharmacol 25(10):818-826, 2022.



Ito S, Miura K, Miyayama M, Matsumoto J, Fukunaga M, Ishimaru K, Fujimoto M, Yasuda
Y, Watanabe Y, Hashimoto R: Association between globus pallidus volume and positive
symptoms in schizophrenia. Psychiatry Clin Neurosci 76(11):602-603 2022.



Okada T, Hori H, Hasegawa N, Murata A, Kyou Y, Kodaka F, Iida H, Ochi S, Takaesu Y,
Tsuboi T, Iga JI, Ichihashi K, Muraoka H, Furihata R, Yasui-Furukori N, Usami M,
Onitsuka T, Ogasawara K, Tagata H, Takeshima M, Ohi K, Numata S,Hashimoto N,
Yamada H, Makinodan M, Komatsu H, Hishimoto A, Yamagata H, Kido M, Kubota C, Atake
K, Yamada H, Nagasawa T, Matsumoto J, Miura K, Inada K, Watanabe K, Suda S,
Hashimoto R: Second-Generation Antipsychotic Monotherapy Contributes to the̿ 86 ̿                   ϩ  ◊ ✲ ά ື ≧ ἣ                    

Discontinuation of Anticholinergic Drugs in Hospitalized Patients With Schizophrenia. J
Clin Psychopharmacol 42(6):591-593 2022.
Kushima I, Aleksic B, Kimura H, Nakatochi M, Lo T, Ikeda M, Arai M, Hashimoto R,
Numata S, Okamura Y, Obara T, Inada T, Ozaki N: X chromosome aneuploidies andschizophrenia: association analysis and phenotypic characterization. Psychiatry Clin
Neurosci 76(12):667-673, 2022.



Kalman JL, Yoshida T, Andlauer TFM, Schulte EC, Adorjan K, Alda M, Ardau R, Aubry JM,
Brosch K, Budde M, Chillotti C, Czerski PM, DePaulo RJ, Forstner A, Goes FS, GrigoroiuSerbanescu M, Grof P, Grotegerd D, Hahn T, Heilbronner M, Hasler R, Heilbronner U,
Heilmann-HeimEDFK6.DSHOVNL3.DWR7.RKVKRXU020HLQHUW60HOOHU71HQDGLþ,
Nothen MM, Novak T, Opel N, Pawlak J, Pfarr JK,Potash JB, Reich-Erkelenz D, Repple J,
Richard-Lepouriel H, Rietschel M, Ringwald KG, Rouleau G, Schaupp S, Senner F, Severino
G, Squassina A, Stein F,Stopkova P, Streit F, Thiel K, Thomas-Odenthal F, Turecki G,
Twarowska-Hauser J,Winter A, Zandi PP, Kelsoe JR, Consortium on Lithium Genetics(ConLiGen), PsyCourse, Falkai P, Dannlowski U, Kircher T, Schulze TG, Papiol S:
Investigating the phenotypic and genetic associations between personality traits andsuicidal behavior across major mental health diagnoses. Eur Arch Psychiatry Clin Neurosci
272(8):1611-1620, 2022.

Inada K, Fukumoto K, Hasegawa N, Yasuda Y, Yamada H, Hori H, Ichihashi K,Iida H, Ohi
K, Muraoka H, Kodaka F, Ide K, Hashimoto N, Iga JI, Ogasawara K, Atake K, Takaesu Y,
Nagasawa T, Komatsu H, Okada T, Furihata R, Kido M, Kikuchi S, Kubota C, Makinodan
M, Ochi S, Takeshima M, Yamagata H, Matsumoto J, Miura K, Usami M, Kishimoto T,
Onitsuka T, Katsumoto E, Hishimoto A, Numata S, Yasui- Furukori N, Watanabe K,
Hashimoto R: Development of individual fitness score for conformity of prescriptions to the"Guidelines For Pharmacological Therapy of Schizophrenia". Neuropsychopharmacol Rep
42(4):502-509, 2022.



Kyou Y, Yasui-Furukori N, Hasegawa N, Ide K, Ichihashi K, Hashimoto N, Hori H, Shimizu
Y, Imamura Y, Muraoka H, Iida H, Ohi K, Yasuda Y, Ogasawara K, Numata S, Iga JI, Tsuboi
T, Ochi S, Kodaka F, Furihata R, Onitsuka T, Makinodan M, Komatsu H, Takeshima M,
Kubota C, Hishimoto A, Atake K, Yamagata H, Kido M, Nagasawa T, Usami M, Kishimoto
T, Kikuchi S, Matsumoto J, Miura K, Yamada H, Watanabe K, Inada K, Hahimoto R: The
characteristics of discharge prescriptions including pro re nata psychotropic medications
for patients with schizophrenia and major depressive disorder from the survey of the"Effectiveness of guidelines for dissemination and education in psychiatric treatment(EGUIDE)" project. Ann Gen Psychiatry 21(1):52, 2022.

Tsuboi T, Takaesu Y, Hasegawa N, Ochi S, Fukumoto K, Ohi K, Muraoka H, Okada T,
Kodaka F, Igarashi S, Iida H, Kashiwagi H, Hori H, Ichihashi K, Ogasawara K, Hashimoto
N, Iga JI, Nakamura T, Usami M, Nagasawa T, Kido M, Komatsu H, Yamagata H, Atake K,
Furihata R, Kikuchi S, Horai T, Takeshima M, Hirano Y, Makinodan M, Matsumoto J,
Miura K, Hishimoto A, Numata S, Yamada H, Yasui-Furukori N, Inada K, Watanabe K,
Hashimoto R: Effects of electroconvulsive therapy on the use of anxiolytics and sleep
medications: a propensity score-matched analysis. Psychiatry Clin Neurosci 77(1):30-37,
2023.



Yamagata H, Tsunedomi R, Kamishikiryo T, Kobayashi A, Seki T, Kobayashi M, Hagiwara
K, Yamada N, Chen C, Uchida S, Ogihara H, Hamamoto Y, Okada G, Fuchikami M, Iga JI,
Numata S, Kinoshita M, Kato TA, Hashimoto R, Nagano H, Ueno S, Okamoto Y, Ohmori T,

̿ 87 ̿                    ⢭⚄ಖ೺◊✲ᡤᖺሗ ➨36ྕ                   Nakagawa S. Interferon signaling and hypercytokinemia-related gene expression in the
blood of antidepressant non-responders. Heliyon 9(1):e13059, 2023.


Fukumoto K, Kodaka F, Hasegawa N, Muraoka H, Hori H, Ichihashi K, Yasuda Y, Iida H,
Ohi K, Ochi S, Ide K, Hashimoto N, Usami M, Nakamura T, Komatsu H, Okada T,
Nagasawa T, Furihata R, Atake K, Kido M, Kikuchi S, Yamagata H, Kishimoto T,
Makinodan M, Horai T, Takeshima M, Kubota C, Asami T, Katsumoto E, Hishimoto A,
Onitsuka T, Matsumoto J, Miura K, Yamada H, Yasui-Furukori N, Watanabe K, Inada K,
Otsuka K, Hashimoto R: Development of an individual fitness score (IFS) based on the
depression treatment guidelines of in the Japanese Society of Mood Disorders.
Neuropsychopharmacol Rep 43(1):33-39, 2023.



Iida H, Okada T, Nemoto K, Hasegawa N, Numata S, Ogasawara K, Miura K, Matsumoto
J, Hori H, Iga JI, Ichihashi K, Hashimoto N, Yamada H, Ohi K, Yasui-Furukori N,
Fukumoto K, Tsuboi T, Usami M, Furihata R, Takaesu Y, Hishimoto A, Muraoka H,
Katsumoto E, Nagasawa T, Ochi S, Komatsu H, Kikuchi S, Takeshima M, Onitsuka T,
Tamai S, Kubota C, Inada K, Watanabe K, Kawasaki H, Hashimoto R: Satisfaction with
web-based courses on clinical practice guidelines for psychiatrists: Findings from the"Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment(EGUIDE)" project. Neuropsychopharmacol Rep 43(1):23-32, 2023.



Korai Y, Miura K: A dynamical model of visual motion processing for arbitrary stimuli
including type II plaids. Neural Netw 162:46-68, 2023.



Ohnishi T, Toda W, Itagaki S, Sato A, Matsumoto J, Ito H, Ishii S, Miura I, Yabe H:
Disrupted structural connectivity and less efficient network system in patients with thetreatment naïve adult attention-deficit/hyperactivity disorder. Frontiers in Psychiatry,

section ADHD 14:1093522 2023.
⏣୰㝧Ꮚ㸪ᐑ⏣⪷Ꮚ㸪ᒾᮏ㑥ᘯ㸪ᒣᮏ┿Ụ㔛㸪୕ᾆ೺୍㑻㸪ᶫᮏுኴ㸪ᑿᓮ⣖ኵ㸸ࢻࣛ࢖ࣅࣥ
ࢢࢩ࣑࣮ࣗࣞࢱ࣮࡟ࡼࡿ೺ᖖ⪅ࡢ㐠㌿ᢏ⾡࡜ど⥺≉ᛶ࡜ࡢ㛵ಀᛶ.᪥ᮏᏳ඲㐠㌿་⒪Ꮫ఍ㄅ㸦㟁Ꮚ∧㸧2(1):46-53, 2022.

 ⥲ㄝ


Hashimoto R: Is it possible to reconstruct the diagnostic system for psychiatric disorders
based on neuroimaging findings? Psychiatry Clin Neurosci 76(5):139, 2022.

Onitsuka T, Hirano Y, Nakazawa T, Ichihashi K, Miura K, Inada K, Mitoma R, YasuiFurukori N, Hashimoto R: Toward recovery in schizophrenia: Current concepts, findings,
and future research directions. Psychiatry Clin Neurosci 76(7):282-291, 2022.

Yasuda Y, Matsumoto J, Miura K, Hasegawa N, Hashimoto R: Genetics of autism spectrum
disorders and future direction. J Hum Genet 68(3):193-197, 2023.
ᶫᮏுኴ㸸⢭⚄⛉㡿ᇦ࡟࠾ࡅࡿከ᪋タඹྠ◊✲ࡢᐇ㝿࡜◊✲೔⌮㸬⢭⚄⚄⤒Ꮫ㞧ㄅ 124 (7):472-478, 2022.
ᶫᮏுኴ㸸᭦ᖺᮇዪᛶࡢ࠺ࡘ⑓ࡢデ᩿ࡢ࣏࢖ࣥࢺ࡜἞⒪ࡢࢥࢶ㸬᪥ᮏዪᛶ་ᏛᏛ఍㞧ㄅ

29(4):628-630, 2022.
ᶫᮏுኴ㸪ᕷᶫ㤶௦㸸ᐙ᪘࣭ᙜ஦⪅ࡶ୍⥴࡟ࡘࡃࡗࡓ⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻࣛ࢖ࣥ 2022㸬

᭶หࡳࢇ࡞ࡡࡗ࡜ 185:6-9, 2022.
ᶫᮏுኴ㸪ᯇᮏ⣧ᘺ㸪㛗㇂ᕝᑦ⨾㸪୕ᾆ೺୍㑻㸸⤫ྜኻㄪ⑕ࡢࣂ࢖࢜ࢱ࢖ࣉ◊✲㸬᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ㄅ 33(4):194-200㸪2022.

ᶫᮏுኴ㸸ࣅࢵࢢࢹ࣮ࢱゎᯒ࠿ࡽ⢭⚄⑌ᝈ࡟㏕ࡿ㸬ࣈ࣮ࣝࣂࢵࢡࢫࠕᚰࡢ⑓ࠖࡢ⬻⛉Ꮫ ࡞ࡏ⏕ࡌࡿࡢ࠿㸪࡝࠺ࡍࢀࡤ἞ࡿ 2224:53-56㸪2023.

̿ 88 ̿                   ϩ  ◊ ✲ ά ື ≧ ἣ                    ୕ᾆ೺୍㑻㸪ᯇᮏ⣧ᘺ㸪᰿ᮏΎ㈗㸪ᶫᮏுኴ㸸⤫ྜኻㄪ⑕ࡢ୰㛫⾲⌧ᆺࢆ⏝࠸ࡓデ᩿࡜ಶู໬
་⒪㸬⮫ᗋ⢭⚄⸆⌮ 26(3):271-277㸪2023.

ᑠụ㐍௓㸪➟஭ΎⓏ㸪ᰗୗ ⚈㸪ᅧ஭ᑦே㸪ᯇᓮᨻ⣖㸪⏣୰ㅬ஧㸪Ᏹ㈡㈗⣖㸪ྜྷ⏣ṇಇ㸪ᒣᮏ┿Ụ㔛㸪㨣ሯಇ᫂㸪୕ᾆ೺୍㑻㸪ᑠᯇ୕బᏊ㸸཮᪉ྥࢺࣛࣥࢫ࣮ࣞࢩࣙࢼࣝ࢔ࣉ࣮ࣟࢳ࡟ࡼࡿ⢭⚄⑌ᝈࡢ⬻ண

ᛶ㞀ᐖᶵᗎ࡟㛵ࡍࡿ◊✲㛤Ⓨ㸬⏕యࡢ⛉Ꮫ 73(5):458-459㸪2022.

୕ᾆ೺୍㑻㸸どぬ᝟ሗࡀ⮬ᕫ⛣ືឤぬ࡟ཬࡰࡍᙳ㡪㸬య⫱ࡢ⛉Ꮫ 72 (11)㸪708-772㸪2022.

 ⴭ᭩
㨣ሯಇ᫂㸪ᶫᮏுኴ㸸⦅ⴭ ⢭⚄་Ꮫ㡿ᇦࡢㄽᩥࢆࡼࡳࡇ࡞ࡍ࣮࣮࢟࣡ࢻ 100㸟㸬᪂⯆་Ꮫฟ∧♫㸪ᮾி㸪pp1-280㸪2022㸬✄ሙ┤Ꮚ㸪୕ᾆ೺୍㑻㸸║⌫㐠ືࡢ✀㢮㸬᪥ᮏどぬᏛ఍⦅㞟㸸ᅗㄝ どぬࡢ஦඾㸬ᮅ಴᭩ᗑ㸪pp180-183㸪2022.
 ◊✲ሗ࿌᭩  ᶫᮏுኴ㸪୕ᾆ೺୍㑻㸪ᯇᮏ⣧ᘺ㸪㛗㇂ᕝᑦ⨾㸸ከḟඖ⬻⚄⤒⏬ീ࡜ࢤࣀ࣒࡟ࡼࡿ⢭⚄⑌ᝈࡢ⬻⑓ែ࡟ᇶ࡙ࡃ᪂ࡓ࡞デ᩿య⣔ࡢᵓ⠏㸬2022 ᖺᗘ⛉Ꮫ◊✲㈝ຓᡂ஦ᴗᇶ┙◊✲㸦B㸧◊✲ᐇ⦼ሗ࿌᭩㸬2023.
  ᶫᮏுኴ㸸Ⓨ㐩㞀ᐖࡢࣜࢫࢡ㑇ఏᏊࡢྠᐃ㸬2022 ᖺᗘ⛉Ꮫ◊✲㈝ຓᡂ஦ᴗ≉ู᥎㐍◊✲ࠕⓎ㐩㞀ᐖ࡟㛵ࢃࡿ⚄⤒⏕≀Ꮫⓗᶵᵓࡢ㟋㛗㢮ⓗᇶ┙ࡢゎ᫂㸦௦⾲㸸㧗⏣ᫀᙪ㸧ࠖ2022 ᖺᗘ◊✲ᐇ⦼ሗ࿌᭩㸬2023㸬  ᶫᮏுኴ㸸ࢡࣟࢨࣆࣥࣔࢽࢱࣜࣥࢢࢩࢫࢸ࣒ࡢᅜ㝿ẚ㍑ㄪᰝ㸬௧࿴ 4 ᖺᗘཌ⏕ປാ⛉Ꮫ◊✲㈝⿵ຓ㔠 㞀ᐖ⪅ᨻ⟇⥲ྜ◊✲஦ᴗ㸦⢭⚄㞀ᐖศ㔝㸧ࠕ἞⒪᢬ᢠᛶ⤫ྜኻㄪ⑕⸆ࡢᏳ඲ᛶࡢ᳨
ド࡟ࡼࡿᮃࡲࡋ࠸ᬑཬ࡜యไᵓ⠏࡟ྥࡅࡓ◊✲㸦௦⾲㸸ୖ㔝㞝ᩥ㸧ࠖศᢸ◊✲ሗ࿌᭩㸬2023㸬  ᶫᮏுኴ㸪୕ᾆ೺୍㑻㸪ᯇᮏ⣧ᘺ㸪Ᏻ⏣⏤⳹㸸⢭⚄⛉㡿ᇦࡢ࢞࢖ࢻࣛ࢖ࣥࡢ♫఍ᐇ⿦໬࡟㛵ࡍࡿ᳨ド◊✲㸬2022 ᖺᗘ᪥ᮏ་⒪◊✲㛤Ⓨᶵᵓ 㞀ᐖ⪅ᑐ⟇⥲ྜ◊✲㛤Ⓨ஦ᴗ㸦⢭⚄㞀ᐖศ
㔝㸧2022 ᖺᗘ ጤク◊✲㛤Ⓨᡂᯝሗ࿌᭩㸬2023㸬  ᶫᮏுኴ㸪୕ᾆ೺୍㑻㸪ᯇᮏ⣧ᘺ㸪Ᏻ⏣⏤⳹㸸AI ᢏ⾡ࢆά⏝ࡋࡓ⤫ྜኻㄪ⑕ࡢ᪩ᮇデ᩿་⒪ᶵჾࣉࣟࢢ࣒ࣛࡢ㛤Ⓨ࡟㛵ࡍࡿ◊✲㸬2022 ᖺᗘ᪥ᮏ་⒪◊✲㛤Ⓨᶵᵓ ་ᕤ㐃ᦠ࣭ேᕤ▱⬟ᐇ⿦◊✲஦ᴗ 2022 ᖺᗘ ጤク◊✲㛤Ⓨᡂᯝሗ࿌᭩㸬2023㸬  ᶫᮏுኴ㸪୕ᾆ೺୍㑻㸪ᯇᮏ⣧ᘺ㸸iPS ⣽⬊ᢏ⾡࡜ࢹ࣮ࢱ⛉Ꮫࢆ⼥ྜࡋࡓ⢭⚄⑌ᝈᶓ᩿ⓗ࡞཮᪉ྥࢺࣛࣥࢫ࣮ࣞࢩࣙࢼࣝ◊✲㸬2022 ᖺᗘ᪥ᮏ་⒪◊✲㛤Ⓨᶵᵓ ⬻࡜ࡇࡇࢁࡢ◊✲᥎㐍ࣉࣟࢢ࣒ࣛ㸦⢭⚄࣭⚄⤒⑌ᝈ࣓࢝ࢽࢬ࣒ゎ᫂ࣉࣟࢪ࢙ࢡࢺ㸧2022 ᖺᗘ ጤク◊✲㛤Ⓨᡂᯝሗ࿌᭩㸬2023㸬  ᶫᮏுኴ㸸Ẽศ㞀ᐖ࡜⤫ྜኻㄪ⑕ࡢ⑌ᝈ㐃⥆ᛶ࡟㛵ࡍࡿ⬻⏬ീ➼ࡢ⥲ྜⓗゎᯒ◊✲㸬2022 ᖺᗘ᪥ᮏ་⒪◊✲㛤Ⓨᶵᵓ ᡓ␎ⓗᅜ㝿⬻⛉Ꮫ◊✲᥎㐍ࣉࣟࢢ࣒ࣛࠕ⦪᩿ⓗ MRI ࢹ࣮ࢱ࡟ᇶ࡙
ࡃᡂேᮇẼศ㞀ᐖ࡜㛵㐃⑌ᝈࡢ⚄⤒ᅇ㊰ࡢゎ᫂㸦◊✲㛤Ⓨ௦⾲⪅㸸ᒸᮏὈᫀ㸧
ࠖ2022 ᖺᗘ ጤク◊✲㛤Ⓨᡂᯝሗ࿌᭩㸬2023㸬  ᶫᮏுኴ㸸⬻⚄⤒⏬ീࡢゎᯒ࡜⦪᩿ࢹ࣮ࢱ࡟ᇶ࡙ࡃ㸪⢭⚄⑌ᝈࡢ἞⒪ຠᯝཬࡧணᚋ࡟㛵ࡍࡿᒙู໬㸬2022 ᖺᗘ᪥ᮏ་⒪◊✲㛤Ⓨᶵᵓ 㞀ᐖ⪅ᑐ⟇⥲ྜ◊✲㛤Ⓨ஦ᴗ㸦⢭⚄㞀ᐖศ㔝㸧ࠕ⢭⚄⑌ᝈࣞࢪࢫࢺࣜࡢ฼ά⏝࡟ࡼࡿ἞⒪ຠᯝ㸪㌿ᖐண㸪᪂ࡓ࡞ᒙู໬࡟㛵ࡍࡿ◊✲㸦◊✲㛤Ⓨ௦⾲⪅㸸୰㎸࿴ᖾ㸧ࠖ2022 ᖺᗘ ጤク◊✲㛤Ⓨᡂᯝሗ࿌᭩㸬2023㸬  ᶫᮏுኴ㸸COVID-19 ⢭⚄⑕≧ࡢࣞࢪࢫࢺࣜ࡟࠾ࡅࡿ⬻⏬ീ཰㞟ࢩࢫࢸ࣒ࡢᵓ⠏࡜ゎᯒ㸬2022 ᖺᗘ᪥ᮏ་⒪◊✲㛤Ⓨᶵᵓ 㞀ᐖ⪅ᑐ⟇⥲ྜ◊✲㛤Ⓨ஦ᴗ㸦⢭⚄㞀ᐖศ㔝㸧
ࠕCOVID-19
ឤᰁᚋࡢ⢭⚄⑕≧ࢆ᭷ࡍࡿᝈ⪅ࣞࢪࢫࢺࣜࡢᵓ⠏࡜⑓ែゎ᫂ཬࡧ᪂つ἞⒪ἲࡢ㛤Ⓨ࡟㈨ࡍࡿ
◊✲㸦◊✲㛤Ⓨ௦⾲⪅㸸㨣㢌ఙ㍜㸧
ࠖ2022 ᖺᗘ ጤク◊✲㛤Ⓨᡂᯝሗ࿌᭩㸬2023㸬  ᶫᮏுኴ㸸ゎᯒᑐ㇟ ASD/SCZ ᐙ⣔ࡢ㑅ᐃ࡜⮫ᗋ᝟ሗࡢ཰㞟㸬2022 ᖺᗘ᪥ᮏ་⒪◊✲㛤Ⓨᶵ̿ 89 ̿                    ⢭⚄ಖ೺◊✲ᡤᖺሗ ➨36ྕ                   ᵓ ࢤࣀ࣒་⒪ᐇ⌧ࣂ࢖࢜ࣂࣥࢡ฼ά⏝ࣉࣟࢢ࣒ࣛ:B-Cure ࢤࣀ࣒་⒪ᐇ⌧᥎㐍ࣉࣛࢵࢺࣇ
࢛࣮࣒࣭ඛ➃ࢤࣀ࣒◊✲㛤Ⓨ஦ᴗࠕ⢭⚄⑌ᝈࡢಶู໬་⒪ࢆᐇ⌧ࡍࡿࡓࡵࡢࢤࣀ࣒࣭✵㛫࣑࢜ࢡࢫከ᪋タඹྠ◊✲㸦◊✲㛤Ⓨ௦⾲⪅㸸ᚨỌ຾ኈ㸧ࠖ2022 ᖺᗘ ጤク◊✲㛤Ⓨᡂᯝሗ࿌᭩㸬2023㸬  ୕ᾆ೺୍㑻㸸║⌫㐠ືࡢ≧ἣணᛶゎᯒἲࡢ◊✲㛤Ⓨ࡜⑌ᝈᶓ᩿ⓗ⌮ゎ㸬2022 ᖺᗘ᪥ᮏ་⒪◊✲㛤Ⓨᶵᵓ 㠉᪂ⓗᢏ⾡࡟ࡼࡿ⬻ᶵ⬟ࢿࢵࢺ࣮࣡ࢡࡢ඲ᐜゎ᫂ࣉࣟࢪ࢙ࢡࢺࠕ཮᪉ྥࢺࣛࣥ
ࢫ࣮ࣞࢩࣙࢼࣝ࢔ࣉ࣮ࣟࢳ࡟ࡼࡿ⢭⚄⑌ᝈࡢ⬻ணᛶ㞀ᐖᶵᗎ࡟㛵ࡍࡿ◊✲㛤Ⓨ㸦◊✲㛤Ⓨ௦⾲⪅㸸ᑠụ㐍௓㸧ࠖ2022 ᖺᗘ ጤク◊✲㛤Ⓨᡂᯝሗ࿌᭩㸬2023㸬  ୕ᾆ೺୍㑻㸪ᯇᮏ⣧ᘺ㸪㛗㇂ᕝᑦ⨾㸸⢭⚄⑌ᝈࡢどぬㄆ▱⾜ື␗ᖖࡢࢩࢫࢸ࣒⚄⤒⛉Ꮫⓗ◊✲㸬2022 ᖺᗘ⛉Ꮫ◊✲㈝ຓᡂ஦ᴗ ᇶ┙◊✲㸦C㸧◊✲ᐇ᪋≧ἣሗ࿌᭩㸬2023㸬  㛗㇂ᕝᑦ⨾㸸⢭⚄⑌ᝈࡢฎ᪉⾜ື࡟࠾ࡅࡿ἞⒪࢞࢖ࢻࣛ࢖ࣥࡢᬑཬ࡜ᩍ⫱ࡢຠᯝ᳨ド㸬2022ᖺᗘ⛉Ꮫ◊✲㈝ຓᡂ஦ᴗ ⱝᡭ◊✲ᐇ᪋≧ἣሗ࿌᭩㸬2023.
 ⩻ヂ ࡑࡢ௚
ᶫᮏுኴ㸦⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻࣛ࢖ࣥ 2022 సᡂ࣓ࣥࣂ࣮㸧㸸⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻࣛ࢖ࣥ 2022(2022 ᖺ 5 ᭶ 20 ᪥බ㛤). ་Ꮫ᭩㝔,2022.

ᶫᮏுኴ㸦⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻ 2022 ࣮࣡࢟ࣥࢢࢢ࣮ࣝࣉ࣓ࣥࣂ࣮㸧㸸⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻ 2022-ᝈ⪅࡜ᨭ᥼⪅ࡢࡓࡵ࡟-(2023 ᖺ 2 ᭶ 15 ᪥බ㛤). 2022.
୰㎸࿴ᖾ㸪ᶫᮏுኴ㸸⢭⚄⛉ᑓ㛛་ࡢࡓࡵࡢᶍᨃࢸࢫࢺ 6㸬᭶ห⢭⚄⛉ 40 (4)㸸553-554㸪2022.

୰㎸࿴ᖾ㸪ᶫᮏுኴ㸸⢭⚄⛉ᑓ㛛་ࡢࡓࡵࡢᶍᨃࢸࢫࢺ 6-ᅇ⟅࡜ゎㄝ-㸬᭶ห⢭⚄⛉ 40 (5)㸸728-732㸪2022.

ᶫᮏுኴ㸸෌ᵓᡂᗙㄯ఍ ᪂Ꮫ⾡㡿ᇦࠕ࣐ࣝࢳࢫࢣ࣮ࣝ⢭⚄⑓ែࡢᵓᡂⓗ⌮ゎࠖḟୡ௦⬻࣭෤ࡢࢩ࣏ࣥࢪ࣒࢘ 2021ࠕᇶ♏⚄⤒⛉Ꮫ࡜⮫ᗋ⢭⚄ࡀ⼥ྜࡋࡓࣈ࣮ࣞࢡࢫ࣮ࣝ◊✲ࡢ⫱࡚᪉ࠖ㸬
MULTISCAL BRAIN News letter 5:7-12㸪2023.
ᯇᮏ⣧ᘺ㸸ࢃࡓࡋࡢ◊✲ ⢭⚄⑌ᝈࡢ⑓ែゎ᫂◊✲㸬᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ㄅ 33(2):87-89㸪



2022.
㹀㸬Ꮫ఍࣭◊✲఍࡟࠾ࡅࡿⓎ⾲ Ꮫ఍≉ูㅮ₇㸪ᩍ⫱ㅮ₇㸪ࢩ࣏ࣥࢪ࣒࢘㸪࣮࣡ࢡࢩࣙࢵࣉ㸪ࣃࢿࣝࢹ࢕ࢫ࢝ࢵࢩࣙࣥ➼ᒸᮏὈᫀ㸪ᶫᮏுኴ㸪ΎỈᰤྖ㸪ᚨ⏣ᬛ☾㸸⦪᩿ⓗ MRI ࢹ࣮ࢱ࡟ᇶ࡙ࡃᡂேᮇẼศ㞀ᐖ࡜㛵㐃⑌ᝈࡢ⚄⤒ᅇ㊰ࡢゎ᫂㸬➨ 118 ᅇ᪥ᮏ⢭⚄⚄⤒Ꮫ఍Ꮫ⾡⥲఍㸪⚟ᒸ㸪2022.6.16.

ᶫᮏுኴ㸸⢭⚄⛉་࡟ᑐࡍࡿㅮ⩦࡟ࡼࡿ࢞࢖ࢻࡢᬑཬ࡜ࡑࡢ⌮ゎࡢྥୖ㸬➨ 118 ᅇ᪥ᮏ⢭⚄⚄⤒Ꮫ఍Ꮫ⾡⥲఍㸪⚟ᒸ㸪2022.6.16.



EGUIDE ࣉࣟࢪ࢙ࢡࢺ㸦௦⾲ ᶫᮏுኴ㸧㸸⢭⚄་⒪ዡບ㈹ཷ㈹ㅮ₇㸪➨ 118 ᅇ᪥ᮏ⢭⚄⚄⤒Ꮫ఍Ꮫ⾡⥲఍㸪⚟ᒸ㸪2022.6.17.

ᶫᮏுኴ㸸⢭⚄⛉἞⒪࢞࢖ࢻࣛ࢖ࣥࡢᩍ⫱࣭ᬑཬ᳨࣭ド࡟ࡼࡗ࡚⮫ᗋ⌧ሙࡢఱࡀኚࢃࡿࡢ࠿㸽㸬㸦බ♫㸧኱㜰⢭⚄⛉デ⒪ᡤ༠఍ R4 ᖺᗘ⥲఍࣭Ꮫ⾡◊✲㞟఍㸪኱㜰㸦࢜ࣥࣛ࢖ࣥ㸧
㸪2022.6.25.

ᶫᮏுኴ㸸ࣄࢺ࣭⢭⚄⑌ᝈ⬻㛵㐃ࢹ࣮ࢱ࣮࣋ࢫࡢ౛㸸COCORO ࡜࣐࢖ࣞࢪࢫࢺࣜ㸬⬻㛵㐃ࢹ࣮ࢱ࣮࣋ࢫᶵ㛵㐃ᦠ࢟ࢵࢡ࢜ࣇࢩ࣏ࣥࢪ࣒࢘㸪࢜ࣥࣛ࢖ࣥ㸪2022.7.27.

ᶫᮏுኴ㸪ᯇᮏ⣧ᘺ㸪㛗㇂ᕝᑦ⨾㸪୕ᾆ೺୍㑻㸸⏕≀Ꮫⓗศ㢮ࢆྲྀࡾධࢀࡓ⢭⚄⑌ᝈデ᩿ࡢᑗ᮶ീ㸬➨ 41 ᅇ᪥ᮏ⢭⚄⛉デ᩿Ꮫ఍㸪࢜ࣥࣛ࢖ࣥ㸪2022.9.9.

ᶫᮏுኴ㸪ᯇᮏ⣧ᘺ㸪㛗㇂ᕝᑦ⨾㸪୕ᾆ೺୍㑻㸸⢭⚄⑌ᝈࡢデ᩿ἲࡢ㛤Ⓨࡣ࡝ࡢࡼ࠺࡟⾜࠺ࡢ࠿㸽㸬➨ 44 ᅇ᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ᖺ఍㸪➨ 32 ᅇ᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ᖺ఍㸪➨ 52
ᅇ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ᖺ఍㸪➨ 6 ᅇ᪥ᮏ⢭⚄⸆Ꮫ఍⥲఍࣭Ꮫ⾡㞟఍ࡢ 4 Ꮫ఍ྜྠᖺ఍

̿ 90 ̿                   ϩ  ◊ ✲ ά ື ≧ ἣ                    

㸦BPCNPNPPP4 Ꮫ఍ྜྠᖺ఍㸧㸪ᮾி㸪2022.11.5.

ᶫᮏுኴ㸸⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻࣛ࢖ࣥ 2022 ࡢసᡂࡢ⤒⦋࡜ᴫせ㸬➨ 44 ᅇ᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ᖺ఍㸪➨ 32 ᅇ᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ᖺ఍㸪➨ 52 ᅇ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ᖺ఍㸪➨ 6 ᅇ᪥ᮏ⢭⚄⸆Ꮫ఍⥲఍࣭Ꮫ⾡㞟఍ࡢ 4 Ꮫ఍ྜྠᖺ఍㸦BPCNPNPPP4 Ꮫ఍ྜྠᖺ఍㸧㸪ᮾி㸪2022.11.4.

ᯇᮏ⣧ᘺ㸪୕ᾆ೺୍㑻㸪ᶫᮏுኴ㸸኱⬻⓶㉁ᵓ㐀⏬ീࡢ኱つᶍࢹ࣮ࢱ࡟ࡼࡿ⢭⚄⑌ᝈᶓ᩿ゎᯒ㸬
➨ 44 ᅇ᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ᖺ఍㸪➨ 32 ᅇ᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ᖺ఍㸪➨ 52 ᅇ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ᖺ఍㸪➨ 6 ᅇ᪥ᮏ⢭⚄⸆Ꮫ఍⥲఍࣭Ꮫ⾡㞟఍ࡢ 4 Ꮫ఍ྜྠᖺ఍
㸦BPCNPNPPP4 Ꮫ఍ྜྠᖺ఍㸧㸪ᮾி㸪2022.11.4.

 ᶫᮏுኴ㸸⢭⚄⛉་⒪ࡢୡ⏺ࢆኚ࠼ࡿࡓࡵࡢ◊✲࡜ࡣ㸸⑓ែ◊✲࠿ࡽ♫఍ᐇ⿦◊✲ࡲ࡛㸬➨ 41ᅇ᪥ᮏ♫఍⢭⚄་Ꮫ఍㸪⚄ᡞ㸪2023.3.17.
ᶫᮏுኴ㸸⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻࣛ࢖ࣥ 2022 ࡢ࣏࢖ࣥࢺ࡜ᬑཬ㸬➨ 41 ᅇ᪥ᮏ♫఍⢭⚄་Ꮫ఍㸪⚄ᡞ㸪2023.3.17.

୕ᾆ೺୍㑻㸸⮫ᗋ⌧ሙ࡛౑࠼ࡿࢱࣈࣞࢵࢺࢆ⏝࠸ࡓ⤫ྜኻㄪ⑕ࡢ⿵ຓデ᩿ἲࡢ㛤Ⓨ㸬➨ 41 ᅇ᪥ᮏ⢭⚄⛉デ᩿Ꮫ఍㸪࢜ࣥࣛ࢖ࣥ㸪2022.9.9.

 ୍⯡₇㢟

Ohi K, Nishizawa D, Sugiyama S, Takai K, Kuramitsu A, Hasegawa J, Soda M, Kitaichi K,
Hashimoto R, Ikeda K, Shioiri T. Polygenic risk scores differentiating schizophrenia frombipolar disorder are associated with premorbid intelligence in schizophrenia patients andhealthy subjects. 2022 Congress of the Schizophrenia International Research Society,
Online, 2022.4.6.



Ohi K, Nishizawa D, Sugiyama S, Takai K, Fujikane D, Kuramitsu A, Hasegawa J, Soda M,
Kitaichi K, Hashimoto R, Ikeda K, Shioiri T. Cognitive Performances across Individuals at
High Genetic Risk for Schizophrenia, High Genetic Risk for Bipolar Disorder, and Low
Genetic Risks: A Combined Polygenic Risk Score Approach. CINP (33rd Committee of theInternational College of Neuropsychopharmacology), Taipei, 2022.6.13.

Ochi S, Tagata H, Hasegawa N, Yasui-Furukori N, Iga JI, Kashiwagi H, Kodaka F, Komatsu
H, Tsuboi T, Tokutani A, Numata S, Ichihashi K, Onitsuka T, Muraoka H, Iida H, Ohi K,
Atake K, Kishimoto T, Hori H, Takaesu Y, Takeshima M Usami M, Makinodan M,
Hashimoto N, Fujimoto M, Furihata R, Nagasawa T, Yamada H, Matsumoto J, Miura K,
Kido M, Hishimoto A, Ueno S, Watanabe K, Inada K, Hashimoto R㸸Clozapine treatment
is associated with higher prescription rate of antipsychotic monotherapy and lower
prescription rate of other concomitant psychotropics: A real-world nationwide study㸬CINP(33rd Committee of the International College of Neuropsychopharmacology), Taipei,
2022.6.12.

Schijven D, Postema MC, ENIGMA-Schizophrenia Working Group, Fisher SE, Franke B,
Glahn DC, Gur RC, Hashimoto R, Jahanshad N, Luders E, Medland SE, Thompson PM,
Turner JA, van Erp TGM, Francks C㸸Large-scale analysis of brain structural asymmetries
in schizophrenia via the ENIGMA consortium㸬2022 OHBM Annual Meeting, Scotland,
2022.6.20.

⏣୰ᑘ㈗㸪ᰗ⃝⌶ྐ㸪⚟㛫Ⰻᖹ㸪㇂ ┤ᶞ㸪ᢲ㔝 ᝅ㸪୕ཎ㞞ྐ㸪᭹㒊᠇᫂㸪Ლᒣ⿱ኴ㸪ᶫᮏுኴ㸪ụ⏣ Ꮫ㸪ᮃ᭶⚽ᶞ㸪㈗ᓥᬕᙪ㸸⬻☢ᅗࢆ⏝࠸ࡓࣃ࣮࢟ࣥࢯࣥ⑓ࡢ఩┦᣺ᖜ࢝ࢵࣉࣜࣥࢢࡢ
ホ౯㸬➨ 45 ᅇ᪥ᮏ⬻⚄⤒ CI Ꮫ఍㸪࢜ࣥࣛ࢖ࣥ㸪2022.4.8.

୰ᮧᩄ⠊㸪㝆᪝㝯஧㸪㛗㇂ᕝᑦ⨾㸪኱ᵳ ᛭㸪ྂ㒆つ㞝㸪ᆤ஭㈗Ⴙ㸪㉺ᬛ⤀୍㑻㸪ᕷᶫ㤶௦㸪ᒣ⏣ ᜏ㸪୕ᾆ೺୍㑻㸪ᯇᮏ⣧ᘺ㸪Ώ㑔⾮୍㑻㸪✄⏣ ೺㸪㮖ሯఙ௓㸪ᶫᮏுኴ㸸⤫ྜኻㄪ⑕ᝈ⪅̿ 91 ̿                    ⢭⚄ಖ೺◊✲ᡤᖺሗ ➨36ྕ                   ࡢධ㝔἞⒪࡟࠾ࡅࡿ╧╀⸆ቑῶࡢ㛵㐃せᅉ㸸඲ᅜㄪᰝࡢศᯒ㸬➨ 118 ᅇ᪥ᮏ⢭⚄⚄⤒Ꮫ఍Ꮫ⾡⥲఍㸪⚟ᒸ㸪2022.6.17.
஬༑ᔒ ಇ㸪ᆤ஭㈗Ⴙ㸪㛗㇂ᕝᑦ⨾㸪ྂ㒆つ㞝㸪㉺ᬛ⤀୍㑻㸪㣤⏣ோᚿ㸪ᮧᒸᐶஅ㸪㧗ỤὪ⩏࿴㸪ᒸ⏣๛ྐ㸪᯽ᮌᏹᏊ㸪ᑠ㧗ᩥ⫄㸪⚟ᮏ೺ኴ㑻㸪୕ᾆ೺୍㑻㸪ᯇᮏ⣧ᘺ㸪✄⏣ ೺㸪Ώ㑔⾮୍㑻㸪ᶫᮏுኴ㸸ධ㝔࠺ࡘ⑓ᝈ⪅࡟࠾ࡅࡿ ECT ᚋࡢⅣ㓟ࣜࢳ࣒࢘ࡢฎ᪉ᐇែ࡟ࡘ࠸࡚㸬➨ 118 ᅇ᪥ᮏ⢭⚄⚄⤒Ꮫ఍Ꮫ⾡⥲఍㸪⚟ᒸ㸪2022.6.17.

኱ᵳ ᛭㸪㝆⡡㝯஧㸪㛗㇂ᕝᑦ⨾, ୰ᮧᩄ⠊㸪ྂ㒆つ㞝㸪ᑠ㧗ᩥ⫄㸪ᇼ ㍤㸪ᆤ஭㈗Ⴙ㸪἟⏣࿘ຓ㸪᯽ᮌᏹᏊ㸪ᯇᮏ⣧ᘺ㸪୕ᾆ೺୍㑻㸪✄⏣ ೺㸪Ώ㑔⾮୍㑻㸪㕥ᮌṇὈ㸪ᶫᮏுኴ㸸᪥ᮏࡢ࠺ࡘ⑓ධ㝔἞⒪࡟࠾ࡅࡿ╧╀⸆ฎ᪉⋡ࡢ᪋タ㛫ࡢ㐪࠸࡜ࡑࡢ㛵㐃せᅉ㸬➨ 118 ᅇ᪥ᮏ⢭⚄⚄⤒Ꮫ఍Ꮫ⾡⥲఍㸪⚟ᒸ㸪2022.6.17.

ᒣᙧᘯ㝯㸪⸨஭ඃᏊ㸪㜝 ཭ᜨ㸪㛗㇂ᕝᑦ⨾㸪ᶫᮏுኴ㸪୰ᕝ ఙ㸸EGUIDE ࣉࣟࢪ࢙ࢡࢺ࡟ࡼ
ࡿ⤫ྜኻㄪ⑕ᝈ⪅࣭࠺ࡘ⑓ᝈ⪅࡟ᑐࡍࡿእ᮶ฎ᪉ࡢኚ໬㸬➨ 118 ᅇ᪥ᮏ⢭⚄⚄⤒Ꮫ఍Ꮫ⾡⥲఍㸪⚟ᒸ㸪2022.6.17.

ᒣᮏဴஓ㸪୕ᾆ೺୍㑻㸪ᯇ⏣ᆂྖ㸪ᯇᮏ⣧ᘺ㸪ᶫᮏுኴ㸪ᑠ㔝ㄔྖ㸪ᐃ⸨つᘯ㸪⚟Ọ㞞႐㸸ࣄࢺࡢ⁥ືᛶ㏣㊧║⌫㐠ື࡟㛵ࢃࡿ⬻㡿ᇦ࡜㧗㧊㠧໬㡿ᇦࡢᑐᛂ㸬Neuro2022 ➨ 45 ᅇ᪥ᮏ⚄⤒⛉Ꮫ኱఍㸭➨ 65 ᅇ᪥ᮏ⚄⤒໬Ꮫ఍኱఍㸭➨ 32 ᅇ᪥ᮏ⚄⤒ᅇ㊰Ꮫ఍኱఍㸪Ἀ⦖㸪2022.6.30.

ᮏᒣ⨾ஂோ㸪ᒣ⏣ ᜏ㸪㛗㇂ᕝᑦ⨾㸪୕ᾆ೺୍㑻㸪ᯇᮏ⣧ᘺ㸪✄⏣ ೺㸪Ώ㑔⾮୍㑻㸪ᶫᮏுኴ㸸⢭⚄⛉ࣞࢪࢹࣥࢺ࡟ᑐࡍࡿ࠺ࡘ⑓἞⒪࢞࢖ࢻࣛ࢖ࣥㅮ⩦ࡢຠᯝࡢ᳨ウ-࢞࢖ࢻࣛ࢖ࣥ࡟ἢࡗࡓ
⮫ᗋ⾜ືᐇ㊶ᗘࡢኚ໬-㸬➨ 19 ᅇ᪥ᮏ࠺ࡘ⑓Ꮫ఍⥲఍㸭➨ 5 ᅇ᪥ᮏ࠺ࡘ⑓࣮ࣜ࣡ࢡ༠఍ᖺḟ኱఍࠙ྜྠ㛤ദࠚ
㸪኱ศ㸪2022.7.14.

ᒣ⏣ ᜏ㸪ᮏᒣ⨾ஂோ㸪㛗㇂ᕝᑦ⨾㸪୕ᾆ೺୍㑻㸪ᯇᮏ⣧ᘺ㸪✄⏣ ೺㸪Ώ㑔⾮୍㑻㸪ᶫᮏுኴ㸸࠺ࡘ⑓἞⒪࢞࢖ࢻࣛ࢖ࣥㅮ⩦ཷㅮຠᯝࡢ᳨ウ-࢞࢖ࢻࣛ࢖ࣥㅮ⩦๓࡜ཷㅮᚋ 5 ᖺ㛫ࡢ࢞࢖ࢻࣛ
࢖ࣥ࡟ἢࡗࡓ⮫ᗋ⾜ືᐇ㊶ᗘࡢኚ໬-㸬➨ 19 ᅇ᪥ᮏ࠺ࡘ⑓Ꮫ఍⥲఍㸭➨ 5 ᅇ᪥ᮏ࠺ࡘ⑓࣮ࣜ࣡
ࢡ༠఍ᖺḟ኱఍࠙ྜྠ㛤ദࠚ㸪኱ศ㸪2022.7.14.

ᒸ⏣๛ྐ㸪⚟ᮏ೺ኴ㑻㸪ᆤ஭㈗Ⴙ㸪㛗㇂ᕝᑦ⨾㸪ᮧᒸᐶஅ㸪᯽ᮌᏹᏊ㸪㉺ᬛ⤀୍㑻㸪஬༑ᔒ ಇ㸪㣤⏣ோᚿ㸪ᑠ㧗ᩥ⫄㸪኱஭୍㧗㸪㧗ỤὪ⩏࿴㸪ྂ㒆つ㞝㸪୕ᾆ೺୍㑻㸪ᯇᮏ⣧ᘺ㸪㡲⏣ྐᮁ㸪✄⏣ ೺㸪Ώ㑔⾮୍㑻㸪ᶫᮏுኴ㸸࠺ࡘ⑓࡟ᑐࡍࡿ⥔ᣢ ECT ᝈ⪅࡟ే⏝ࡍࡿ⸆≀⒪ἲࡢᐇែ㸬➨ 19 ᅇ᪥ᮏ࠺ࡘ⑓Ꮫ఍⥲఍㸭➨ 5 ᅇ᪥ᮏ࠺ࡘ⑓࣮ࣜ࣡ࢡ༠఍ᖺḟ኱఍࠙ྜྠ㛤ദࠚ㸪኱ศ㸪

2022.7.14.
ᮧᒸᐶஅ㸪㛗㇂ᕝᑦ⨾㸪ྂ㒆つ㞝㸪ᑠ㧗ᩥ⫄㸪⚟ᮏ೺ኴ㑻㸪᯽ᮌᏹᏊ㸪኱஭୍㧗㸪ᯇᮏ⣧ᘺ㸪୕ᾆ೺୍㑻㸪✄⏣ ೺㸪Ώ㑔⾮୍㑻㸪すᮧ຾἞ 㸪ᶫᮏுኴ㸸࠺ࡘ⑓ࡢ἞⒪࡟ᑐࡍࡿ EGUIDE ㅮ⩦ࡢຠᯝ࡜㔜⑕ᗘࡢ௜グࡢᙳ㡪㸬➨ 19 ᅇ᪥ᮏ࠺ࡘ⑓Ꮫ఍⥲఍㸭➨ 5 ᅇ᪥ᮏ࠺ࡘ⑓࣮ࣜ࣡ࢡ༠
఍ᖺḟ኱఍࠙ྜྠ㛤ദࠚ㸪኱ศ㸪2022.7.14.

ᶫᮏ┤ᶞ㸪ྂ㒆つ㞝㸪἟⏣࿘ຓ㸪㣤⏣ோᚿ㸪ᕷᶫ㤶௦㸪✄⏣ ೺㸪㝆⡡㝯஧㸪ᇼ ㍤㸪ᑠ㧗ᩥ⫄㸪㛗㇂ᕝᑦ⨾㸪ᶫᮏுኴ㸸ධ㏥㝔᫬ฎ᪉ࡢẚ㍑࠿ࡽࡳࡓ㸪ᢠ࠺ࡘ⸆༢๣἞⒪ࡢᐇែㄪᰝ-EGUIDEࣉࣟࢪ࢙ࢡࢺࢹ࣮ࢱࡼࡾ-㸬➨ 19 ᅇ᪥ᮏ࠺ࡘ⑓Ꮫ఍⥲఍㸭➨ 5 ᅇ᪥ᮏ࠺ࡘ⑓࣮ࣜ࣡ࢡ༠఍ᖺḟ኱఍࠙ྜྠ㛤ദࠚ㸪኱ศ㸪2022.7.14.

Kitagawa K, Baba M, Takemoto T, Nagayasu K, Kasai A, Takuma K, Hashimoto R,
Hashimoto H, Ago Y, Nakazawa T㸸Impaired neurodevelopment in iPS cell-derived neuralstem cells from psychiatric patients with 7q36.3 microduplication㸬VPAC-ISBAP2022㸦The
15th International Symposium on VIP, PACAP and Related Peptides The 1st International
Society for BioactivePeptides Meeting㸧, Osaka, 2022.10.30.

ᶫᮏ┤ᶞ㸪ྂ㒆つ㞝㸪἟⏣࿘ຓ㸪㣤⏣ோᚿ㸪ᕷᶫ㤶௦㸪㝆⡡㝯஧㸪ᇼ ㍤㸪ᑠ㧗ᩥ⫄㸪㛗㇂ᕝᑦ⨾㸪ᯇᮏ⣧ᘺ㸪୕ᾆ೺୍㑻㸪Ώ㑔⾮୍㑻㸪✄⏣ ೺㸪ᶫᮏுኴ㸸ධ㏥㝔᫬ฎ᪉ࡢẚ㍑࠿ࡽࡳࡓᢠ
⢭⚄⑓⸆༢๣἞⒪ࡢᐇែㄪᰝ -EGUIDE ࣉࣟࢪ࢙ࢡࢺࢹ࣮ࢱࡼࡾ-㸬➨ 44 ᅇ᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ᖺ఍㸪➨ 32 ᅇ᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ᖺ఍㸪➨ 52 ᅇ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ᖺ఍㸪̿ 92 ̿                   ϩ  ◊ ✲ ά ື ≧ ἣ                    ➨ 6 ᅇ᪥ᮏ⢭⚄⸆Ꮫ఍⥲఍࣭Ꮫ⾡㞟఍ࡢ 4 Ꮫ఍ྜྠᖺ఍㸦BPCNPNPPP4 Ꮫ఍ྜྠᖺ఍㸧㸪ᮾி㸪2022.11.5.
㛗㇂ᕝᑦ⨾㸪Ᏻ⏣⏤⳹㸪ྂ㒆つ㞝㸪ᕷᶫ㤶௦㸪ᑠ㧗ᩥ⫄㸪ᇼ ㍤㸪㣤⏣ோᚿ㸪ᮧᒸᐶஅ㸪㧗ỤὪ⩏࿴㸪୕ᾆ೺୍㑻㸪ᯇᮏ⣧ᘺ㸪✄⏣ ೺㸪Ώ㑔⾮୍㑻㸪ᶫᮏுኴ㸸⤫ྜኻㄪ⑕࡜࠺ࡘ⑓ࡢ἞⒪࡟
ᑐࡍࡿ EGUIDE ࣉࣟࢪ࢙ࢡࢺࡢຠᯝ㸸4 ᖺ㛫ࡢ⤒ᖺⓗኚ໬࡟╔┠ࡋ࡚㸬➨ 44 ᅇ᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ᖺ఍㸪➨ 32 ᅇ᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ᖺ఍㸪➨ 52 ᅇ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ᖺ఍㸪➨ 6 ᅇ᪥ᮏ⢭⚄⸆Ꮫ఍⥲఍࣭Ꮫ⾡㞟఍ࡢ 4 Ꮫ఍ྜྠᖺ఍㸦BPCNPNPPP4 Ꮫ఍ྜྠᖺ఍㸧㸪ᮾி㸪2022.11.5.

ఀ⸨㣁ጲ㸪୕ᾆ೺୍㑻㸪ᐑᒣᮍ᮶஀㸪ᯇᮏ⣧ᘺ㸪⚟Ọ㞞႐㸪▼୸ᚄ୍㑻㸪⸨ᮏ⨾ᬛᏊ㸪Ᏻ⏣⏤⳹㸪Ώ㑓჆அ㸪ᶫᮏுኴ㸸⤫ྜኻㄪ⑕࡟࠾ࡅࡿῐ⵬⌫ࡢ⫧኱໬࡜㝧ᛶ⑕≧ࡢ㔜⑕ᗘࡢ㛵㐃㸬➨44 ᅇ᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ᖺ఍㸪➨ 32 ᅇ᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ᖺ఍㸪➨ 52 ᅇ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ᖺ఍㸪➨ 6 ᅇ᪥ᮏ⢭⚄⸆Ꮫ఍⥲఍࣭Ꮫ⾡㞟఍ࡢ 4 Ꮫ఍ྜྠᖺ఍㸦BPCNPNPPP4Ꮫ఍ྜྠᖺ఍㸧㸪ᮾி㸪2022.11.5.

ᒣ㷂㱟୍㸪ᯇᮏ⣧ᘺ㸪᰿ᮏΎ㈗㸪⚟Ọ㞞႐㸪ᶫᮏ┤ᶞ㸪ᑠ㧗ᩥ⫄㸪㧘㔝ᬕᡂ㸪ఀ⸨㣁ጲ㸪㛗㇂ᕝᑦ⨾㸪Ᏻ⏣⏤⳹㸪⸨ᮏ⨾ᬛᏊ㸪ᒣ᳃ⱥ㛗㸪Ώ㑓჆அ㸪୕ᾆ೺୍㑻㸪ᶫᮏுኴ㸸⤫ྜኻㄪ⑕࡟
≉ᚩⓗ࡞⬻య✚ῶᑡࣃࢱ࣮ࣥࡢ⤒᫬ኚ໬㸬➨ 44 ᅇ᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ᖺ఍㸪➨ 32 ᅇ᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ᖺ఍㸪➨ 52 ᅇ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ᖺ఍㸪➨ 6 ᅇ᪥ᮏ⢭⚄⸆Ꮫ఍⥲఍࣭Ꮫ⾡㞟఍ࡢ 4 Ꮫ఍ྜྠᖺ఍㸦BPCNPNPPP4 Ꮫ఍ྜྠᖺ఍㸧㸪ᮾி㸪2022.11.5.

ᒸ㷂ᗣ㍜㸪୕ᾆ೺୍㑻㸪ᯇᮏ⣧ᘺ㸪㛗㇂ᕝᑦ⨾㸪⸨ᮏ⨾ᬛᏊ㸪ᒣ᳃ⱥ㛗㸪Ᏻ⏣⏤⳹㸪∾அẁ Ꮫ㸪ᶫᮏுኴ㸸║⌫㐠ື࡜ㄆ▱ᶵ⬟ࢆ⤌ࡳྜࢃࡏ࡟ࡼࡿ⤫ྜኻㄪ⑕ࡢ⿵ຓデ᩿ἲࡢ㛤Ⓨ㸸ᶵᲔᏛ⩦ἲ࡟ࡼࡿ᳨ウ㸬➨ 44 ᅇ᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ᖺ఍㸪➨ 32 ᅇ᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ᖺ఍㸪➨ 52 ᅇ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ᖺ఍㸪➨ 6 ᅇ᪥ᮏ⢭⚄⸆Ꮫ఍⥲఍࣭Ꮫ⾡㞟఍ࡢ 4 Ꮫ఍ྜྠᖺ఍㸦BPCNPNPPP4 Ꮫ఍ྜྠᖺ఍㸧㸪ᮾி㸪2022.11.5.

ᐑᒣᮍ᮶஀㸪୕ᾆ೺୍㑻㸪ఀ⸨㣁ጲ㸪ᯇᮏ⣧ᘺ㸪⚟Ọ㞞႐㸪▼୸ᚄ୍㑻㸪⸨ᮏ⨾ᬛᏊ㸪Ᏻ⏣⏤⳹㸪ᒣ᳃ⱥ㛗㸪Ώ㑓჆அ㸪ᶫᮏுኴ㸸⤫ྜኻㄪ⑕࡟࠾ࡅࡿປാ᫬㛫࡜⬻ᵓ㐀ࡢ㛵㐃ཬࡧㄆ▱ᶵ⬟㞀ᐖࡢ፹௓ຠᯝࡢ᳨ウ㸬➨ 44 ᅇ᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ᖺ఍㸪➨ 32 ᅇ᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ᖺ఍㸪➨ 52 ᅇ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ᖺ఍㸪➨ 6 ᅇ᪥ᮏ⢭⚄⸆Ꮫ఍⥲఍࣭Ꮫ⾡㞟఍ࡢ 4Ꮫ఍ྜྠᖺ఍㸦BPCNPNPPP4 Ꮫ఍ྜྠᖺ఍㸧㸪ᮾி㸪2022.11.4.

㓇஭ెỌ㸪ఀ⸨㣁ጲ㸪ᯇᮏ⣧ᘺ㸪Ᏻ⏣⏤⳹㸪ᒣ᳃ⱥ㛗㸪⸨ᮏ⨾ᬛᏊ㸪㛗㇂ᕝᑦ⨾㸪▼୸ᚄ୍㑻㸪୕ᾆ೺୍㑻㸪ᶫᮏுኴ㸸⤫ྜኻㄪ⑕ᝈ⪅࡟࠾ࡅࡿ⑓㆑ࡢ⤒᫬ⓗኚ໬ࡢࣃࢱ࣮ࣥ࡜㛵㐃ࡍࡿ⮫ᗋⓗせᅉ㸬➨ 44 ᅇ᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ᖺ఍㸪➨ 32 ᅇ᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ᖺ఍㸪➨ 52
ᅇ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ᖺ఍㸪➨ 6 ᅇ᪥ᮏ⢭⚄⸆Ꮫ఍⥲఍࣭Ꮫ⾡㞟఍ࡢ 4 Ꮫ఍ྜྠᖺ఍
㸦BPCNPNPPP4 Ꮫ఍ྜྠᖺ఍㸧㸪ᮾி㸪2022.11.4.

㉺ᬛ⤀୍㑻㸪⏣ᙧᘯᐇ㸪㛗㇂ᕝᑦ⨾㸪ྂ㒆つ㞝㸪ఀ㈡῟୍㸪᯽ᮌᏹᏊ㸪ᑠ㧗ᩥ⫄㸪ᑠᯇ ᾈ㸪ᆤ஭㈗Ⴙ㸪ᚨ㇂ ᫭㸪἟⏣࿘ຓ㸪ᓊᮏὈኈ㑻㸪ᇼ ㍤㸪⳻ᮏ᫂㇏㸪ᯇᮏ⣧ᘺ㸪୕ᾆ೺୍㑻㸪ୖ㔝ಟ୍㸪Ώ㑔⾮୍㑻㸪✄⏣ ೺㸪ᶫᮏுኴ㸸ࢡࣟࢨࣆࣥ἞⒪ࡣᢠ⢭⚄⑓⸆ࡢ㧗࠸༢๣⋡࠾ࡼࡧ௚ࡢྥ
⢭⚄⸆ࡢప࠸ే⏝⋡࡟㛵㐃ࡍࡿ㸬➨ 44 ᅇ᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ᖺ఍㸪➨ 32 ᅇ᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ᖺ఍㸪➨ 52 ᅇ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ᖺ఍㸪➨ 6 ᅇ᪥ᮏ⢭⚄⸆Ꮫ఍⥲఍࣭Ꮫ⾡㞟఍ࡢ 4 Ꮫ఍ྜྠᖺ఍㸦BPCNPNPPP4 Ꮫ఍ྜྠᖺ఍㸧㸪ᮾி㸪2022.11.4.

㧗⏣ᬛᘯ㸪ᶫᮏ ᆒ㸪ᶫᮏுኴ㸪୰⃝ᩗಙ㸸2p16.3 㡿ᇦḞኻࢆ᭷ࡍࡿ⢭⚄⑌ᝈᝈ⪅ࡢ iPS ⣽⬊⏤᮶⚄⤒⣔⣽⬊ࡢᶵ⬟ゎᯒ㸬➨ 44 ᅇ᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ᖺ఍㸪➨ 32 ᅇ᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ᖺ఍㸪➨ 52 ᅇ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ᖺ఍㸪➨ 6 ᅇ᪥ᮏ⢭⚄⸆Ꮫ఍⥲఍࣭Ꮫ⾡㞟఍ࡢ
4 Ꮫ఍ྜྠᖺ఍㸦BPCNPNPPP4 Ꮫ఍ྜྠᖺ఍㸧㸪ᮾி㸪2022.11.4.

ᯇᮏ⣧ᘺ㸪⚟Ọ㞞႐㸪୕ᾆ೺୍㑻㸪᰿ᮏΎ㈗㸪ᒸ⏣┤኱㸪ᶫᮏ┤ᶞ㸪᳃⏣೺ኴ㑻㸪㉺ᒣኴ㍜㸪኱஭୍㧗㸪㧗ᶫ ດ㸪⫧⏣㐨ᙪ㸪ᒣ᳃ⱥ㛗㸪⸨ᮏ⨾ᬛᏊ㸪Ᏻ⏣⏤⳹㸪㛗㇂ᕝᑦ⨾㸪ఀ⸨㣁ጲ㸪 ᡂ⏣ ᑦ㸪ᶓᒣோྐ㸪୕ᔱ ு㸪ἙᓥᏕᙪ㸪ᑠᯘ♸Ꮚ㸪➲ᯘ኱ᶞ㸪ཎ⏣೺୍㑻㸪ᒣᮏ┿Ụ㔛㸪ᖹ㔝

̿ 93 ̿                    ⢭⚄ಖ೺◊✲ᡤᖺሗ ➨36ྕ                   ⨺Ⴙ㸪ᯈᶫ㈗ྐ㸪୰℧⌮ோ㸪ᶫᮏ㱟୍㑻㸪ࢱ ࢟ࣥ࢟ࣥ㸪ᑠụ㐍௓㸪ᯇཎᩄ㑻㸪ᒸ⏣ ๛㸪ྜྷᮧ⋹ඣ㸪㜿㒊 ಟ㸪㨣ሯಇ᫂㸪Ώ㑔჆அ㸪ᯇᑿᖾ἞㸪ᒣᮎⱥ඾㸪ᒸᮏὈᫀ㸪㕥ᮌ㐨㞝㸪ᑿᓮ⣖ኵ㸪➟஭ΎⓏ㸪ᶫᮏுኴ㸸⤫ྜኻㄪ⑕࣭཮ᴟᛶ㞀ᐖ࣭࠺ࡘ⑓࣭⮬㛢ࢫ࣌ࢡࢺ࣒ࣛ⑕ࡢከ᪋タ኱つᶍࢹ࣮ࢱ࡟ࡼࡿ⑌ᝈᶓ᩿ⓗ࡞኱⬻⓶㉁ᵓ㐀ࡢ㢮ఝᗘࡢゎᯒ㸬➨ 44 ᅇ᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ᖺ఍㸪➨ 32 ᅇ᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ᖺ఍㸪➨ 52 ᅇ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ᖺ఍㸪➨ 6 ᅇ᪥ᮏ⢭⚄⸆Ꮫ఍⥲఍࣭Ꮫ⾡㞟఍ࡢ 4 Ꮫ఍ྜྠᖺ఍㸦BPCNPNPPP4 Ꮫ఍ྜྠᖺ఍㸧㸪ᮾி㸪2022.11.4.
ᮏᒣ⨾ஂோ㸪ᒣ⏣ ᜏ㸪㛗㇂ᕝᑦ⨾㸪୕ᾆ೺୍㑻㸪ᯇᮏ⣧ᘺ㸪✄⏣ ೺㸪Ώ㑔⾮୍㑻㸪ᶫᮏுኴ㸸⢭⚄⛉ࣞࢪࢹࣥࢺ࡟ᑐࡍࡿ⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻࣛ࢖ࣥㅮ⩦ࡢຠᯝࡢ᳨ウ-࢞࢖ࢻࣛ࢖ࣥ
࡟ἢࡗࡓ⮫ᗋ⾜ືᐇ㊶ᗘࡢẚ㍑-㸬➨ 44 ᅇ᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ᖺ఍㸪➨ 32 ᅇ᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ᖺ఍㸪➨ 52 ᅇ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ᖺ఍㸪➨ 6 ᅇ᪥ᮏ⢭⚄⸆Ꮫ఍⥲఍࣭Ꮫ⾡㞟఍ࡢ 4 Ꮫ఍ྜྠᖺ఍㸦BPCNPNPPP4 Ꮫ఍ྜྠᖺ఍㸧㸪ᮾி㸪2022.11.4.

ᒣ⏣ ᜏ㸪ᮏᒣ⨾ஂோ㸪㛗㇂ᕝᑦ⨾㸪୕ᾆ೺୍㑻㸪ᯇᮏ⣧ᘺ㸪✄⏣ ೺㸪Ώ㑔⾮୍㑻㸪ᶫᮏுኴ㸸࢞࢖ࢻࣛ࢖ࣥㅮ⩦ཷㅮ๓࡜ཷㅮᚋ 5 ᖺ㛫ࡢ⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻࣛ࢖ࣥ࡟ἢࡗࡓ⮫ᗋ⾜ືᐇ㊶ᗘࡢኚ໬-἞⒪࢞࢖ࢻࣛ࢖ࣥᩍ⫱ࣉࣟࢪ࢙ࢡࢺ㸦EGUIDE ࣉࣟࢪ࢙ࢡࢺ㸧ࡢຠᯝ᳨ウ㸬➨ 44 ᅇ᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ᖺ఍㸪➨ 32 ᅇ᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ᖺ఍㸪➨ 52 ᅇ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ᖺ఍㸪➨ 6 ᅇ᪥ᮏ⢭⚄⸆Ꮫ఍⥲఍࣭Ꮫ⾡㞟఍ࡢ 4 Ꮫ఍ྜྠᖺ఍
㸦BPCNPNPPP4 Ꮫ఍ྜྠᖺ఍㸧㸪ᮾி㸪2022.11.4.

ఫྜྷࢳ࢝㸪ఀ⸨㣁ጲ㸪ᯇᮏ⣧ᘺ㸪⸨㔝㝧⏕㸪ᒣ᳃ⱥ㛗㸪⸨ᮏ⨾ᬛᏊ㸪Ᏻ⏣⏤⳹㸪୕ᾆ೺୍㑻㸪ఫྜྷኴᖿ㸪ᶫᮏுኴ㸸⢭⚄⑕≧࣭♫఍ᶵ⬟࡟ᇶ࡙ࡃ⤫ྜኻㄪ⑕ᝈ⪅ࡢປാ≧ែࡢ᥎ᐃ࣭ண

㸬➨ 17 ᅇ᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍㸪࢜ࣥࣛ࢖ࣥ㸪2023.3.25.
ᶫᮏ┤ᶞ㸪᰿ᮏΎ㈗㸪⚟Ọ㞞႐㸪ᯇᮏ⣧ᘺ㸪୕ᾆ೺୍㑻㸪ᒸ⏣┤኱㸪᳃⏣೺ኴ㑻㸪㉺ᒣኴ㍜㸪኱஭୍㧗㸪㧗ᶫ ດ㸪⫧⏣㐨ᙪ㸪ᒣ᳃ⱥ㛗㸪⸨ᮏ⨾ᬛᏊ㸪Ᏻ⏣⏤⳹㸪㛗㇂ᕝᑦ⨾㸪ఀ⸨㣁ጲ㸪ᡂ⏣ ᑦ㸪ᶓᒣோྐ㸪୕ᔱ ு㸪ἙᓥᏕᙪ㸪ᑠᯘ♸Ꮚ㸪➲ᯘ኱ᶞ㸪ཎ⏣೺୍㑻㸪ᒣᮏ┿Ụ㔛㸪ᖹ㔝⨺Ⴙ㸪ᯈᶫ㈗ྐ㸪୰℧⌮ோ㸪ᶫᮏ㱟୍㑻㸪ࢱ ࢟ࣥ࢟ࣥ㸪ᑠụ㐍௓㸪ᯇཎᩄ㑻㸪ᒸ⏣ ๛㸪ྜྷᮧ⋹ඣ㸪㜿㒊 ಟ㸪㨣ሯಇ᫂㸪Ώ㑔჆அ㸪ᯇᑿᖾ἞㸪ᒣᮎⱥ඾㸪ᒸᮏὈᫀ㸪㕥ᮌ㐨㞝㸪ᑿᓮ⣖ኵ㸪➟஭ΎⓏ㸪ᶫᮏுኴ㸸⬻ᵓ㐀⏬ീࢆ⏝࠸ࡓ⤫ྜኻㄪ⑕ࡽࡋࡉࡢ࣓࢞࢔ࢼࣛ࢖ࢩࢫ㸬➨ 17 ᅇ᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍㸪࢜ࣥࣛ࢖ࣥ㸪2023.3.26.

㨣ሯಇ᫂㸪ᒸ⏣๛ྐ㸪㛗㇂ᕝᑦ⨾㸪ᆤ஭㈗Ⴙ㸪ఀ㈡῟୍㸪ྂ㒆つ㞝㸪ᒣ⏣┤㍤㸪ᇼ ㍤㸪ᮧᒸᐶஅ㸪኱஭୍㧗㸪ᑠ➟ཎ୍⬟㸪㉺ᬛ⤀୍㑻㸪➉ᓥṇᾈ㸪ᕷᶫ㤶௦㸪⚟ᮏ೺ኴ㑻㸪㣤⏣ோᚿ㸪ᒣ⏣ᜏ㸪㝆⡡㝯஧㸪∾அẁ Ꮫ㸪㧗ỤὪ⩏࿴㸪἟⏣࿘ຓ㸪ᑠᯇ ᾈ㸪⳻ᮏ᫂㇏㸪ᮌᡞᖿ㞝㸪㜿➉⪷࿴㸪ᒣᙧᘯ㝯㸪⳥ᆅ⣪⪨㸪ᶫᮏ┤ᶞ㸪Ᏹబ⨾ᨻⱥ㸪຾ඖᴿ୍㸪ὸぢ ๛㸪ஂಖ⏣ᬛ㤶㸪ᯇᮏ⣧ᘺ㸪୕ᾆ೺୍㑻㸪ᖹ㔝⨺Ⴙ㸪Ώ㑔⾮୍㑻㸪✄⏣ ೺㸪ᶫᮏுኴ㸸ᣢ⥆ᛶᢠ⢭⚄⑓ὀᑕ⸆๣㸦LAI㸧࡜⤒ཱྀᢠ⢭⚄⑓⸆ࡢే⏝⸆ࡢ≧ἣ㸸᪥ᮏ࡟࠾ࡅࡿᐇែㄪᰝ㸬➨ 17 ᅇ᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍㸪࢜ࣥࣛ࢖ࣥ㸪2023.3.26.

ᒣ㷂㱟୍㸪ᯇᮏ⣧ᘺ㸪ఀ⸨㣁ጲ㸪᰿ᮏΎ㈗㸪⚟Ọ㞞႐㸪ᶫᮏ┤ᶞ㸪ᑠ㧗ᩥ⫄㸪㧘㔝ᬕᡂ㸪㛗㇂ᕝᑦ⨾㸪Ᏻ⏣⏤⳹㸪⸨ᮏ⨾ᬛᏊ㸪ᒣ᳃ⱥ㛗㸪Ώ㑓჆அ㸪୕ᾆ೺୍㑻㸪ᶫᮏுኴ㸸⬻ᵓ㐀⏬ീୖࡢࠕ⤫ྜኻㄪ⑕ࡽࡋࡉࠖࡢ⦪᩿ኚ໬㸬➨ 17 ᅇ᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍㸪࢜ࣥࣛ࢖ࣥ㸪2023.3.26.

ఀ⸨㣁ጲ㸪୕ᾆ೺୍㑻㸪ᐑᒣᮍ᮶஀㸪ᯇᮏ⣧ᘺ㸪⚟Ọ㞞႐㸪▼୸ᚄ୍㑻㸪⸨ᮏ⨾ᬛᏊ㸪Ᏻ⏣⏤⳹㸪Ώ㑓჆அ㸪ᶫᮏுኴ㸸⤫ྜኻㄪ⑕࡟࠾ࡅࡿῐ⵬⌫య✚࡜⢭⚄⑕≧ࡢ㔜⑕ᗘࡢ㛵㐃㸬➨ 17 ᅇ᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍㸪࢜ࣥࣛ࢖ࣥ㸪2023.3.26.

ᐑᒣᮍ᮶஀㸪୕ᾆ೺୍㑻㸪ఀ⸨㣁ጲ㸪ᯇᮏ⣧ᘺ㸪⚟Ọ㞞႐㸪▼୸ᚄ୍㑻㸪⸨ᮏ⨾ᬛᏊ㸪Ᏻ⏣⏤⳹㸪ᒣ᳃ⱥ㛗㸪Ώ㑓჆அ㸪ᶫᮏுኴ㸸፹௓ศᯒ࡟ࡼࡿ⤫ྜኻㄪ⑕ᝈ⪅ࡢປാ᫬㛫㸪ㄆ▱ᶵ⬟㞀ᐖཬࡧ⬻ᵓ㐀ࡢ㛵㐃᳨ウ㸬➨ 17 ᅇ᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍㸪࢜ࣥࣛ࢖ࣥ㸪2023.3.26.

ᯇᮏ⣧ᘺ㸪ᒣ㷂㱟୍㸪᰿ᮏΎ㈗㸪⚟Ọ㞞႐㸪ᑠ㧗ᩥ⫄㸪㧘㔝ᬕᡂ㸪ఀ⸨㣁ጲ㸪㛗㇂ᕝᑦ⨾㸪୕ᾆ೺୍㑻㸪ᶫᮏுኴ㸸SARS-CoV-2 ឤᰁ๓ᚋ࡛ࡢ⬻ MRI ᡤぢ᳨ウ㸸⤫ྜኻㄪ⑕⑕౛ሗ࿌㸬➨
17 ᅇ᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍㸪࢜ࣥࣛ࢖ࣥ㸪2023.3.26.

̿ 94 ̿                   ϩ  ◊ ✲ ά ື ≧ ἣ                    ⚟ᮏ೺ኴ㑻㸪✄⏣ ೺㸪㛗㇂ᕝᑦ⨾㸪Ᏻ⏣⏤⳹㸪ᇼ ㍤㸪ᕷᶫ㤶௦㸪㣤⏣ோᚿ㸪኱஭୍㧗㸪ᮧᒸᐶஅ㸪ᑠ㧗ᩥ⫄㸪ᯇᮏ⣧ᘺ㸪୕ᾆ೺୍㑻㸪ྂ㒆つ㞝㸪Ώ㑔⾮୍㑻㸪ᶫᮏுኴ㸸⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻ࡟ᇶ࡙࠸ࡓ἞⒪㐺ྜᗘ (individual fitness score)ࡢ㛤Ⓨ㸬➨ 17 ᅇ᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍㸪࢜ࣥࣛ࢖ࣥ㸪2023.3.26.
➉ᮏᬛဢ㸪➉ᮏᬛဢ㸪㤿ሙඃᚿ㸪໭ᕝ⯟ᖹ㸪ỌᏳ୍ᶞ㸪ໃຊ ⸅㸪᪩⏣ᩔᏊ㸪➟஭῟ྖ㸪࿃㒓⏤ᕼኵ㸪⏣⇃ᷧᩏ㸪ᶫᮏுኴ㸪ᶫᮏ ᆒ㸪୰⃝ᩗಙ㸸ࣄࢺᰁⰍయ 3q29 㡿ᇦḞኻࢆᑟධࡋࡓ⮬㛢ࢫ࣌ࢡࢺ࣒ࣛ⑕ࣔࢹ࣐ࣝ࢘ࢫࡢ♫఍⾜ື␗ᖖࡣ࢜࢟ࢩࢺࢩࣥࡢᢞ୚࡟ࡼࡾᅇ᚟ࡍࡿ㸬᪥ᮏ⸆Ꮫ఍
➨ 143 ᖺ఍㸪ᮐᖠ㸪2023.3.26.
⛅ᮏ♸ᘺ㸪㤿ሙඃᚿ㸪⚟ᓥ✑㧗㸪୕ᾆ኱ᶞ㸪ᶫᮏ ᆒ㸪ᶫᮏுኴ㸪୰⃝ᩗಙ㸸⎔ቃ࢚ࣥࣜࢵ
ࢳ࣓ࣥࢺ࡟ࡼࡿ 3q29 㡿ᇦḞኻᑟධ࣐࢘ࢫࡢ⢭⚄⑌ᝈᵝ⾜ືࡢᅇ᚟㸬᪥ᮏ⸆Ꮫ఍➨ 143 ᖺ఍㸪ᮐᖠ㸪2023.3.27.

㧗⏣ᬛᘯ㸪Ἑ㔝⩧ኴ㑻㸪㩗⃝᭷ᕼᏊ㸪୕ᾆ኱ᶞ㸪⚟ᓥ✑㧗㸪ᶫᮏுኴ㸪ᶫᮏ ᆒ㸪୰⃝ᩗಙ㸸ᝈ⪅ iPS ⣽⬊⏤᮶ศ໬⚄⤒⣔⣽⬊ࢆ⏝࠸ࡓ 2p16.3 㡿ᇦḞኻኚ␗ࡢศᏊ⑓ែゎᯒ㸬᪥ᮏ⸆Ꮫ఍➨ 143 ᖺ఍㸪ᮐᖠ㸪2023.3.27.

Ἑ㔝⩧ኴ㑻㸪㧗⏣ᬛᘯ㸪㩗⃝᭷ᕼᏊ㸪୕ᾆ኱ᶞ㸪⚟ᓥ✑㧗㸪ᶫᮏுኴ㸪ᶫᮏ ᆒ㸪୰⃝ᩗಙ㸸ᝈ⪅ iPS ⣽⬊⏤᮶ศ໬⚄⤒⣔⣽⬊ࢆ⏝࠸ࡓ 3q29 㡿ᇦḞኻኚ␗ࡢศᏊ⑓ែゎᯒ㸬᪥ᮏ⸆Ꮫ఍
➨ 143 ᖺ఍㸪ᮐᖠ㸪2023.3.27.

➉ᮧ ᩥ㸪୕ᾆ೺୍㑻㸸ࢧࣝ኱⬻⓶㉁ MTS 㔝ࡢ⚄⤒άືࡣ௬⌧㐠ືࡢ่⃭㛫㛫㝸࡟ࡼࡿ཯㌿ࢆㄝ᫂ࡍࡿ㸬Neuro2022 ➨ 45 ᅇ᪥ᮏ⚄⤒⛉Ꮫ኱఍㸭➨ 65 ᅇ᪥ᮏ⚄⤒໬Ꮫ఍኱఍㸭➨ 32 ᅇ᪥ᮏ⚄⤒ᅇ㊰Ꮫ఍኱఍㸪Ἀ⦖㸪2022.6.30.

ᒣᮏဴஓ㸪⚟Ọ㞞႐㸪୕ᾆ೺୍㑻㸪ᐃ⸨つᘯ㸸▷᫬㛫Ᏻ㟼᫬ fMRI ࢹ࣮ࢱࢆ⏝࠸ࡓ Multimodal
Surface Matching ࡢ㠀 HCP ㄢ㢟 fMRI ゎᯒ࡬ࡢ㐺⏝㸬➨ 50 ᅇ᪥ᮏ☢Ẽඹ㬆་Ꮫ఍኱఍㸪ྡྂᒇ㸪2022.9.11.

ሷ㇂ె௓㸪ᯘ ࿴Ꮚ㸪ᯇᮏ᭷ኸ㸪ᯇ⏣ᆂྖ㸪୕ᾆ೺୍㑻㸪ᒣ᰿ ⱱ㸪Eldridge M.A.G㸪Saunders
R.C㸪Richmond B.J㸪Ọ஭⿱ྖ㸪ᐑᕝᑦஂ㸪༡ᮏᩗྐ㸪∦ୖ ⯗㸪ᒸ⏣┿ே㸪Ἑ㔝᠇஧㸪Ⳣ⏕ᐑᮏᗣᏊ㸸ࢧࣝഃ㢌⓶㉁࡟࠾ࡅࡿ㢦᝟ሗ࡜㢦㉁ឤ᝟ሗࡢ᫬㛫ⓗ⾲⌧㸬ᮾி⌮⛉኱Ꮫࣃࣛࣞࣝ⬻ࢭࣥࢩࣥࢢ◊✲㒊㛛➨ 2 ᅇබ㛤ࢩ࣏ࣥࢪ࣒࢘ࠕThink Synch Brain Dynamics 㹼⌮ᕤࡀᣮࡴ⬻⛉Ꮫ㹼ࠖ㸪ᮾி㸪2022.12.17.

ΎỈᑗᾏ㸪∦ୖ ⯗㸪ᒸ⏣┿ே㸪Ⳣ⏕-ᐑᮏᗣᏊ㸪ᯘ ࿴Ꮚ㸪ᯇ⏣ᆂྖ㸪୕ᾆ೺୍㑻㸪Eldridge M.A.G㸪
Saunders R.C㸪Richmond B.J㸪ᯇᮏ᭷ኸ㸸࢝ࢸࢦ࣮ࣜศ㢮࡟࠾ࡅࡿ TE 㔝࡜ TEO 㔝ࡢࢽ࣮ࣗࣟࣥ≉ᛶẚ㍑㸬
ᮾி⌮⛉኱Ꮫࣃࣛࣞࣝ⬻ࢭࣥࢩࣥࢢ◊✲㒊㛛➨ 2 ᅇබ㛤ࢩ࣏ࣥࢪ࣒࢘ࠕThink
Synch Brain Dynamics 㹼⌮ᕤࡀᣮࡴ⬻⛉Ꮫ㹼ࠖ㸪ᮾி㸪2022.12.17.

㧗㯇㞝௓㸪୕ᾆ೺୍㑻㸸㐠ືどぬࡢືⓗ᪉⛬ᘧ࣮ṧീຠᯝࢆ⪃៖ࡋࡓᣑᙇ࣮㸬➨ 18 ᅇ✵㛫ㄆ▱࡜㐠ືไᚚ◊✲఍㸪ி㒔㸪2023.3.11.

➉ᮧ ᩥ㸪୕ᾆ೺୍㑻㸸ࢣࢱ࣑ࣥ࡟ࡼࡿ࣐࢝ࢡࢨࣝࡢ║⌫㐠ື≉ᛶ࡬ࡢᙳ㡪㸬᪥ᮏ⏕⌮Ꮫ఍➨100 ᅇグᛕ኱఍㸪ி㒔㸪2023.3.14.

Hayashi K, Matsumoto N, Matsuda K, Miura K, Yamane S, Eldridge M.A.G, Saunders R.C,
Richmond B.J, Nagai Y, Miyakawa N, Minamimoto T, Okada M, Kawano K, SugaseMiyamoto Y㸸 Neural and behavioral correlates of discriminating facial expressions withdifferent skin textures in macaque monkeys㸬The 100th Annivesary Annual Meeting of The
Physiological Society of Japan, Kyoto, 2023.3.14.

Kawano K, Hayashi K, Matsumoto M, Matsuda K, Miura K, Eldridge M, Saunders R,
Richmond B, Sugase-Miyamoto Y㸸Effects of saccadic eye movements on face-responsive
neurons in the inferior temporal cortex of macaque monkeys㸬The 100th Annivesary AnnualMeeting of The Physiological Society of Japan, Kyoto, 2023.3.14.
ሷ㇂ె௓㸪ᯘ ࿴Ꮚ㸪ᯇᮏ᭷ኸ㸪ᯇ⏣ᆂྖ㸪୕ᾆ೺୍㑻㸪ᒣ᰿ ⱱ㸪Eldridge M.A.G㸪Saunders

̿ 95 ̿                    ⢭⚄ಖ೺◊✲ᡤᖺሗ ➨36ྕ                   

R.C㸪Richmond B.J㸪Ọ஭⿱ྖ㸪ᐑᕝᑦஂ㸪༡ᮏᩗྐ㸪∦ୖ ⯗㸪ᒸ⏣┿ே㸪Ἑ㔝᠇஧㸪Ⳣ⏕ᐑᮏᗣᏊ㸸࣐࢝ࢡࢨࣝഃ㢌ⴥ TE 㔝ࢽ࣮ࣗࣟࣥࡢ㢦⾲㠃≉ᛶࡢ⾲⌧㸬᪥ᮏ≀⌮Ꮫ఍ 2023 ᖺ᫓Ꮨ኱఍㸪࢜ࣥࣛ࢖ࣥ㸪2023.3.25.
ᯇᮏ⣧ᘺ㸸4 ኱⢭⚄⑌ᝈ࡟࠾ࡅࡿ኱⬻⓶㉁ᵓ㐀⏬ീࡢ⑌ᝈᶓ᩿ゎᯒ㸬ᅜ㝿Ꮫ఍Ⓨ⾲ዡບ㈹ཷ㈹⪅ࢭࢵࢩࣙࣥ㸪➨ 17 ᅇ᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍㸪࢜ࣥࣛ࢖ࣥ㸪2023.3.25.

㛗㇂ᕝᑦ⨾㸸⤫ྜኻㄪ⑕࡜࠺ࡘ⑓ࡢ἞⒪࡟ᑐࡍࡿ EGUIDE ࣉࣟࢪ࢙ࢡࢺࡢຠᯝ㸸2016㹼2019ᖺࡢฎ᪉ㄪᰝ⤖ᯝࡼࡾ㸬ᅜ㝿Ꮫ఍Ⓨ⾲ዡບ㈹ཷ㈹⪅ࢭࢵࢩࣙࣥ㸪➨ 17 ᅇ᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍㸪࢜ࣥࣛ࢖ࣥ㸪2023.3.25.

 ◊✲ሗ࿌఍
ᶫᮏுኴ㸸JART10000 ࣉࣟࢪ࢙ࢡࢺ㸬➨ 18 ᅇ COCORO ྜྠ఍㆟㸪࢜ࣥࣛ࢖ࣥ㸪2022.6.5.

ᶫᮏுኴ㸸COCORO ࡢᴫせ㸬➨ 18 ᅇ COCORO ྜྠ఍㆟㸪࢜ࣥࣛ࢖ࣥ㸪2022.6.5.

୕ᾆ೺୍㑻㸸⢭⚄⑌ᝈᶓ᩿ⓗࢧ࢚ࣜࣥࢩ࣮ゎᯒ㸦║⌫㐠ື㸧㸬࢜ࣥࣛ࢖ࣥ㸪2022.6.5.

ᯇᮏ⣧ᘺ㸸ENIGMA_CDJ_Cortical㸪➨ 18 ᅇ COCORO ྜྠ఍㆟㸬࢜ࣥࣛ࢖ࣥ㸪2022.6.5.

ఀ⸨㣁ጲ㸸⤫ྜኻㄪ⑕࡟࠾ࡅࡿῐ⵬⌫࡜㝧ᛶ⑕≧ࡢ㛵㐃ゎᯒ㸬➨ 18 ᅇ COCORO ྜྠ఍㆟㸪࢜ࣥࣛ࢖ࣥ㸪2022.6.5.
ᐑᒣᮍ᮶஀㸸⤫ྜኻㄪ⑕࡟࠾ࡅࡿປാ᫬㛫࡜⬻ᵓ㐀ࡢ㛵㐃ゎᯒ㸬➨ 18 ᅇ COCORO ྜྠ఍㆟㸪࢜ࣥࣛ࢖ࣥ㸪2022.6.5.

ᶫᮏுኴ㸸⢭⚄⑌ᝈࡢᕧ኱ࢹ࣮ࢱ࣮࣋ࢫࡢ฼ά⏝ࢹ࣮ࢱ࡟ᇶ࡙ࡃ⮫ᗋ▱࡟ࡼࡿᇶ♏⮫ᗋ㐃ᦠ◊✲࡜ࡣ㸬௧࿴ 4 ᖺᗘ AMED ⬻࡜ࡇࡇࢁࡢ◊✲᥎㐍ࣉࣟࢢ࣒ࣛ ⢭⚄࣭⚄⤒⑌ᝈ࣓࢝ࢽࢬ࣒ゎ᫂ࣉࣟࢪ࢙ࢡࢺศ⛉఍㸪࢜ࣥࣛ࢖ࣥ㸪2022.8.19.

ᶫᮏுኴ㸸COCORO ࡢᴫせ㸬➨ 19 ᅇ COCORO ྜྠ఍㆟㸪࢜ࣥࣛ࢖ࣥ㸪2022.12.4.
୕ᾆ೺୍㑻㸸⢭⚄⑌ᝈᶓ᩿ⓗࢧ࢚ࣜࣥࢩ࣮ゎᯒ㸦║⌫㐠ື㸬➨ 19 ᅇ COCORO ྜྠ఍㆟㸪࢜ࣥࣛ࢖ࣥ㸪2022.12.4.

 ᯇᮏ⣧ᘺ㸸ENIGMA_CDJ_Cortical㸬➨ 19 ᅇ COCORO ྜྠ఍㆟㸪࢜ࣥࣛ࢖ࣥ㸪2022.12.4.
 ᯇᮏ⣧ᘺ㸸JART10000 ࣉࣟࢪ࢙ࢡࢺ㸬➨ 19 ᅇ COCORO ྜྠ఍㆟㸪࢜ࣥࣛ࢖ࣥ㸪2022.12.4.
 㛗㇂ᕝᑦ⨾㸪Ᏻ⏣⏤⳹㸪ྂ㒆つ㞝㸪ᕷᶫ㤶௦㸪ᑠ㧗ᩥ⫄㸪ᇼ ㍤㸪㣤⏣ோᚿ㸪ᮧᒸᐶஅ㸪㧗ỤὪ⩏࿴㸪୕ᾆ೺୍㑻㸪ᯇᮏ⣧ᘺ㸪✄⏣ ೺㸪Ώ㑔⾮୍㑻㸪ᶫᮏுኴ㸸⤫ྜኻㄪ⑕࡜࠺ࡘ⑓ࡢ἞⒪࡟
ᑐࡍࡿ EGUIDE ࣉࣟࢪ࢙ࢡࢺࡢຠᯝ㸬ᅜ❧⢭⚄࣭⚄⤒་⒪◊✲ࢭࣥࢱ࣮⢭⚄ಖ೺◊✲ᡤ௧࿴㸲ᖺᗘ◊✲ሗ࿌఍㸪࢜ࣥࣛ࢖ࣥ㸪2023.3.20.

 ᯇᮏ⣧ᘺ㸪⚟Ọ㞞႐㸪୕ᾆ೺୍㑻㸪᰿ᮏΎ㈗㸪ᒸ⏣┤኱㸪ᶫᮏ┤ᶞ㸪᳃⏣೺ኴ㑻㸪㉺ᒣኴ㍜㸪኱஭୍㧗㸪㧗ᶫ ດ㸪⫧⏣㐨ᙪ㸪ᒣ᳃ⱥ㛗㸪⸨ᮏ⨾ᬛᏊ㸪Ᏻ⏣⏤⳹㸪ఀ⸨㣁ጲ㸪ᒣ㷂㱟୍㸪㛗㇂ᕝᑦ⨾㸪ᡂ⏣ ᑦ㸪ᶓᒣோྐ㸪୕ᔱ ு㸪ᐑ⏣ ῟㸪ᑠᯘ♸Ꮚ㸪➲ᯘ኱ᶞ㸪ཎ⏣೺୍㑻㸪ᒣᮏ┿Ụ㔛㸪ᖹ㔝⨺Ⴙ㸪ᯈᶫ㈗ྐ㸪୰℧⌮ோ㸪ᶫᮏ㱟୍㑻㸪ࢱ ࢟ࣥ࢟ࣥ㸪ᑠụ㐍௓㸪ᯇཎᩄ㑻㸪ᒸ⏣ ๛㸪ྜྷᮧ⋹ඣ㸪㜿㒊 ಟ㸪㨣ሯಇ᫂㸪Ώ㑔჆அ㸪ᯇᑿᖾ἞㸪ᒣᮎⱥ඾㸪ᒸᮏὈᫀ㸪㕥ᮌ㐨㞝㸪ᑿᓮ⣖ኵ㸪➟஭ΎⓏ㸪ᶫᮏுኴ㸸4 ኱⢭⚄⑌ᝈࡢ኱⬻ᵓ㐀ࡢ㢮ఝᗘࡢゎᯒ㸸኱⬻⓶㉁ཌ࡜኱⬻⓶㉁⾲
㠃✚ࡢከ᪋タඹྠ⑌ᝈᶓ᩿ゎᯒ㸬ᅜ❧⢭⚄࣭⚄⤒་⒪◊✲ࢭࣥࢱ࣮⢭⚄ಖ೺◊✲ᡤ௧࿴㸲ᖺᗘ◊✲ሗ࿌఍㸪࢜ࣥࣛ࢖ࣥ㸪2023.3.20.
 ࡑࡢ௚
ᶫᮏுኴ㸸ヨᩱ࣭᝟ሗࡢ⮫ᗋⓗព⩏ࢆඹ᭷ࡋ࡚⾜࠺⏘Ꮫ㐃ᦠඹྠ◊✲࡜ࡣ.ᩥ㒊⛉Ꮫ┬ ◊✲᣺⯆ᒁࣛ࢖ࣇࢧ࢖࢚ࣥࢫㄢ୺ദ ࣛ࢖ࣇࢧ࢖࢚ࣥࢫ⛉Ꮫ〇⸆༠࡜ࡢពぢ஺᥮఍㸪2022.11.7.

㹁㸬ㅮ₇




ᶫᮏுኴ㸸ࣜ࢔࣮ࣝ࣡ࣝࢻࡢ⢭⚄་⒪ࡢၥ㢟ࢆゎỴࡍࡿࡓࡵࡢ◊✲࡜ࡣ㸽㸬➨ 49 ᅇ NCNP ⢭⚄ಖ೺◊✲ᡤࣛࣥࢳࣙࣥࢭ࣑ࢼ࣮㸪ᮾி㸪2022.4.25.

̿ 96 ̿                   ϩ  ◊ ✲ ά ື ≧ ἣ                    ᶫᮏுኴ㸸⤫ྜኻㄪ⑕ࡢㄆ▱ᶵ⬟㞀ᐖࡢホ౯࡜἞⒪࡟㛵ࡍࡿᑗ᮶ᒎᮃ㸬ఫ཭ࣇ࢓࣮࣐ओ࣓ࢹ࢕
࢝ࣝ࢔ࣇ࢙࢔࣮ࢬ㒊♫ෆ◊ಟ఍㸪࢜ࣥࣛ࢖ࣥ㸪2022.9.20,

ᶫᮏுኴ㸸⢭⚄⑌ᝈࡢඞ᭹࡜ࡑࡢ㞀ᐖᨭ᥼ࡢࡓࡵ࡟⮫ᗋ⌧ሙࡢ⢭⚄⛉་ࡀ⾜࠺◊✲࡜ࡣ㸬ᚨᓥ኱Ꮫ⢭⚄⛉་ᒁࢭ࣑ࢼ࣮㸪ᚨᓥ㸪2022.11.16.

ᶫᮏுኴ㸸⢭⚄⑌ᝈࡢඞ᭹࡜ࡑࡢ㞀ᐖᨭ᥼ࡢࡓࡵࡢ◊✲࡜ࡣ㸬៞᠕⩏ሿ኱Ꮫ་Ꮫ㒊⢭⚄⛉ࢭ࣑ࢼ࣮㸪࢜ࣥࣛ࢖ࣥ㸪2022.11.30.

ᶫᮏுኴ㸸ᢠ⢭⚄⑓⸆ࡢ㐺ṇ౑⏝ 㹼⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻࣛ࢖ࣥ 2022 ࢆࡩࡲ࠼࡚㹼㸬
Tardive Dyskinesia WEB seminar㸪࢜ࣥࣛ࢖ࣥ㸪2022.12.14.

㹂㸬Ꮫ఍άື Ꮫ఍୺ദ Ꮫ఍ᙺဨ
ᶫᮏுኴ㸸᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ ⌮஦㸪ホ㆟ဨ㸪ᗈሗጤဨ఍ጤဨ㸪⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻ
ࣛ࢖ࣥࢱࢫࢡࣇ࢛࣮ࢫ㸪ᅜ㝿Ꮫ⾡ጤဨ఍ጤဨ㸪ᇳ⾜ጤဨ఍ጤဨ㸪ࢡࣟࢨࣆࣥ TF ጤဨ఍ጤဨ㛗㸪ࢺࣛࣥࢫ࣮ࣞࢩࣙࢼ࣭࣓ࣝࢹ࢕࢝ࣝࢧ࢖࢚ࣥࢫ㸦TMS㸧ጤဨ఍࢖ࣀ࣮࣋ࢩࣙࣥࢧ࢖࢚ࣥࢫ㒊఍ጤဨ㸪⢭⚄⛉἞⒪࢞࢖ࢻࣛ࢖ࣥࡢᬑཬ࣭ᩍ⫱᳨࣭ドጤဨ఍ጤဨ㛗㸦㏻⛠㸸EGUIDE ጤဨ఍㸧㸪⤫ྜኻㄪ⑕デ⒪࢞࢖ࢻࣛ࢖ࣥጤဨ㛗㸪デ⒪࢞࢖ࢻࣛ࢖ࣥጤဨ఍ጤဨ㛗㸪⸆஦ጤဨ఍ጤဨ㸪⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻ 2022 సᡂ࣮࣡࢟ࣥࢢࢢ࣮ࣝࣉ
ᶫᮏுኴ㸸᪥ᮏ⢭⚄⚄⤒Ꮫ఍ PCN ⦅㞟ጤဨ఍ጤဨ㸪⸆஦ጤဨ఍ጤဨ㸪⢭⚄་Ꮫ◊✲᥎㐍ጤဨ఍ጤဨ㸪PCN Reports ⦅㞟ጤဨ఍㸪࢞࢖ࢻࣛ࢖᳨ࣥウጤဨ఍ጤဨ㸪ᥦゝసᡂ࣮࣡࢟ࣥࢢࢢ࣮ࣝ
ࣉ㸪╔ᗋ๓デ᩿࡟㛵ࡍࡿ࣮࣡࢟ࣥࢢࢢ࣮ࣝࣉ 2022 ᖺᗘጤဨᶫᮏுኴ㸸᪥ᮏ⚄⤒໬Ꮫ఍ ホ㆟ဨ㸪⬻◊✲᥎㐍ጤဨ఍ጤဨ㸪㐃ྜ኱఍࣭ከศ㔝஺ὶጤဨ఍ጤဨ

ᶫᮏுኴ㸸᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍ ホ㆟ဨᶫᮏுኴ㸸᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ ホ㆟ဨ㸪⢭⚄⛉἞⒪࢞࢖ࢻࣛ࢖ࣥࡢᬑཬ࣭ᩍ⫱᳨࣭ドጤဨ఍ጤဨ㛗㸦㏻⛠㸸EGUIDE ጤဨ఍㸧ᶫᮏுኴ㸸᪥ᮏ࠺ࡘ⑓Ꮫ఍ ホ㆟ဨ㸪Ẽศ㞀ᐖࡢ἞⒪࢞࢖ࢻࣛ࢖᳨ࣥウጤဨ఍ጤဨ㸪⢭⚄⛉἞⒪࢞࢖ࢻࣛ࢖ࣥࡢᬑཬ࣭ᩍ⫱᳨࣭ドጤဨ఍ጤဨ㛗㸦㏻⛠㸸EGUIDE ጤဨ఍㸧ᶫᮏுኴ㸸᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ ⌮஦㸪ᑗ᮶ィ⏬ጤဨ఍ጤဨ㸦㢳ၥ㸧㸪ᗈሗጤဨ఍ጤဨ㸪㛵㐃Ꮫ఍ᑐᛂጤဨ఍๪ጤဨ㛗㸪ホ㆟ဨᶫᮏுኴ㸸᪥ᮏ⚄⤒⛉ᏛᏛ఍ ⮫ᗋ࣭㛵㐃Ꮫ఍㐃ᦠጤဨ఍ጤဨ

ᶫᮏுኴ㸸ᅜ㝿⚄⤒⢭⚄⸆⌮Ꮫ఍ ⌮஦㸪ࣇ࢙࣮ࣟࢩࢵࣉ⾲ᙲጤဨ఍ጤဨ㸪ᩍ⫱ጤဨ఍ጤဨ㸪ホ㆟ဨ ᗙ㛗

ᶫᮏுኴ㸸⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻࣛ࢖ࣥ 2022 ࡢᴫㄝ㸬➨ 118 ᅇ᪥ᮏ⢭⚄⚄⤒Ꮫ఍Ꮫ⾡⥲఍㸪⚟ᒸ㸪2022.6.18.

ᶫᮏுኴ㸸⢭⚄⛉࡛ᮏᙜ࡟ᚲせ࡞⸆ࡣఱ࠿㸽-⢭⚄⛉࡟࠾ࡅࡿྜពᙧᡂࢆ┠ᣦࡋ࡚-㸬➨ 118 ᅇᶫᮏுኴ㸸⢭⚄⛉デ᩿࡟୍▼ࢆᢞࡌࡿ⏕≀Ꮫⓗ⢭⚄་Ꮫࡢ⌧≧࡜ㄢ㢟㸬➨ 41 ᅇ᪥ᮏ⢭⚄⛉デ᪥ᮏ⢭⚄⚄⤒Ꮫ఍Ꮫ⾡⥲఍㸪⚟ᒸ㸪2022.6.18.
᩿Ꮫ఍㸪࢜ࣥࣛ࢖ࣥ㸪2022.9.9.

ᶫᮏுኴ㸸཮ᴟᛶ㞀ᐖ࡟࠾ࡅࡿデ᩿㸪἞⒪ࡢᬑཬၨⓎ㸬➨ 35 ᅇ᪥ᮏ⥲ྜ⑓㝔⢭⚄་Ꮫ఍⥲఍ࣛࣥࢳࣙࣥࢭ࣑ࢼ࣮㸪ᮾி㸪2022.10.29.

ᶫᮏுኴ㸸᭱ඛ➃ࡢ⢭⚄་Ꮫ◊✲ࡣ⢭⚄⑌ᝈࡢデ᩿ἲࡢ㛤Ⓨ࡟࡝ࡇࡲ࡛㏕ࢀࡿ࠿㸽㸬➨ 44 ᅇ᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ᖺ఍㸪➨ 32 ᅇ᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ᖺ఍㸪➨ 52 ᅇ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ᖺ఍㸪➨ 6 ᅇ᪥ᮏ⢭⚄⸆Ꮫ఍⥲఍࣭Ꮫ⾡㞟఍ࡢ 4 Ꮫ఍ྜྠᖺ఍㸦BPCNPNPPP4 Ꮫ఍̿ 97 ̿                    ⢭⚄ಖ೺◊✲ᡤᖺሗ ➨36ྕ                   ྜྠᖺ఍㸧㸪ᮾி㸪2022.11.5.

ᶫᮏுኴ㸸⢭⚄⛉࢞࢖ࢻࣛ࢖ࣥࢆ⮫ᗋ࡟࠸࠿࡟⏕࠿ࡍ࠿~ྛ⑌ᝈ࢞࢖ࢻࣛ࢖ࣥࡢ࣏࢖ࣥࢺ࡜ά
⏝㸬➨ 41 ᅇ᪥ᮏ♫఍⢭⚄་Ꮫ఍㸪⚄ᡞ㸪2023.3.17.

ᶫᮏுኴ㸸デ⒪࢞࢖ࢻࣛ࢖ࣥ࠿ࡽࡳࡓ⸆≀἞⒪᭱๓⥺㸬➨ 17 ᅇ᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍㸪࢜ࣥࣛ࢖ࣥ㸪2023.3.25.
 Ꮫ఍ㄅ⦅㞟ጤဨ➼ᶫᮏுኴ㸸᪥ᮏ⢭⚄⚄⤒Ꮫ఍ᶵ㛵ㄅࠕPsychiatry and Clinical Neuroscienceࠖ⦅㞟ጤဨ఍ጤဨ

ᶫᮏுኴ㸸᪥ᮏ⢭⚄⚄⤒Ꮫ఍ᶵ㛵ㄅࠕPsychiatry and Clinical Neurosciences Reportsࠖ⦅㞟ጤဨ఍ጤဨᶫᮏுኴ㸸᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ᶵ㛵ㄅࠕNeuropsychopharmacology Reportsࠖࠕ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ㞧ㄅࠖ⦅㞟ጤဨ఍ጤဨ㹃㸬◊ಟ ◊ಟ௻⏬ᶫᮏுኴ㸸➨ 118 ᅇ᪥ᮏ⢭⚄⚄⤒Ꮫ఍Ꮫ⾡⥲఍࣮࣡ࢡࢩࣙࢵࣉ㸪WS:デ⒪ᢏ⾡ྥୖ࣮࣡ࢡࢩࣙ
ࢵࣉ㹼⤫ྜኻㄪ⑕ᝈ⪅࡬ࡢ἞⒪௓ධࢆᏛࡪ㹼㸬⚟ᒸ㸪2022.6.16.

ᶫᮏுኴ㸸኱㜰⢭⚄⛉デ⒪ᡤ༠఍㸪࠺ࡘ⑓἞⒪࢞࢖ࢻࣛ࢖ࣥㅮ⩦఍㸬࢜ࣥࣛ࢖ࣥ㸪2022.7.9.

ᶫᮏுኴ㸸⍇⍈†⑓㝔㸪EGUIDE ࢡࣜࢽ࢝ࣝࣉࣛࢡࢸ࢕ࢫㅮ⩦఍㸬኱ὠ㸪2022.8.6.

ᶫᮏுኴ㸸2022 ᖺᗘᅜ❧⢭⚄࣭⚄⤒་⒪◊✲ࢭࣥࢱ࣮⢭⚄ಖ೺࡟㛵ࡍࡿᢏ⾡◊ಟ㸪➨ 1 ᅇ⤫ྜኻㄪ⑕ࡢᶆ‽἞⒪◊ಟ㸬࢜ࣥࣛ࢖ࣥ㸪2022.8.28.

ᶫᮏுኴ㸸2022 ᖺᗘᅜ❧⢭⚄࣭⚄⤒་⒪◊✲ࢭࣥࢱ࣮⢭⚄ಖ೺࡟㛵ࡍࡿᢏ⾡◊ಟ㸪➨ 1 ᅇ࠺ࡘ⑓ࡢᶆ‽἞⒪◊ಟ㸬࢜ࣥࣛ࢖ࣥ㸪2022.9.4.

ᶫᮏுኴ㸸኱㜰⢭⚄⛉デ⒪ᡤ༠఍㸪⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻࣛ࢖ࣥ 2022 ㅮ⩦఍㸬࢜ࣥࣛ࢖ࣥ㸪2022.9.10.

ᶫᮏுኴ㸸EGUIDE ࣉࣟࢪ࢙ࢡࢺ㛵ᮾ NCNP ㅮ⩦㸪⤫ྜኻㄪ⑕ࡢ࢞࢖ࢻࣛ࢖ࣥㅮ⩦㸬ᮾி㸪

2022.10.2.
ᶫᮏுኴ㸸EGUIDE ࣉࣟࢪ࢙ࢡࢺ㛵ᮾ NCNP ㅮ⩦㸪࠺ࡘ⑓ࡢ࢞࢖ࢻࣛ࢖ࣥㅮ⩦㸬ᮾி㸪

2022.10.16.
ᶫᮏுኴ㸸EGUIDE ࣉࣟࢪ࢙ࢡࢺ໭ᾏ㐨/໭㝣/୰㒊/୰ᅜㅮ⩦㸪⤫ྜኻㄪ⑕ࡢ࢞࢖ࢻࣛ࢖ࣥㅮ

ᶫᮏுኴ㸸EGUIDE ࣉࣟࢪ࢙ࢡࢺ໭ᾏ㐨/໭㝣/୰㒊/୰ᅜㅮ⩦㸪࠺ࡘ⑓ࡢ࢞࢖ࢻࣛ࢖ࣥㅮ⩦㸬࢜⩦㸬࢜ࣥࣛ࢖ࣥ㸪2022.10.29.
ࣥࣛ࢖ࣥ㸪2022.10.30.
ᶫᮏுኴ㸸➨ 44 ᅇ᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ᖺ఍㸪➨ 32 ᅇ᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ᖺ఍㸪➨52 ᅇ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ᖺ఍㸪➨ 6 ᅇ᪥ᮏ⢭⚄⸆Ꮫ఍⥲఍࣭Ꮫ⾡㞟఍ࡢ 4 Ꮫ఍ྜྠᖺ఍
㸦BPCNPNPPP4 Ꮫ఍ྜྠᖺ఍㸧࣮࣡ࢡࢩࣙࢵࣉ㸪⸆๣ᖌࡢࡓࡵࡢ EGUIDE ࣉࣟࢪ࢙ࢡࢺ࣡
࣮ࢡࢩࣙࢵࣉ㸬ᮾி㸪2022.11.5.

ᶫᮏுኴ㸸➨ 44 ᅇ᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ᖺ఍㸪➨ 32 ᅇ᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ᖺ఍㸪➨52 ᅇ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ᖺ఍㸪➨ 6 ᅇ᪥ᮏ⢭⚄⸆Ꮫ఍⥲఍࣭Ꮫ⾡㞟఍ࡢ 4 Ꮫ఍ྜྠᖺ఍
㸦BPCNPNPPP4 Ꮫ఍ྜྠᖺ఍㸧࣮࣡ࢡࢩࣙࢵࣉ㸪⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻࣛ࢖ࣥㅮ⩦఍
㸦EGUIDE ࣉࣟࢪ࢙ࢡࢺ㸧㸬ᮾி㸪2022.11.6.

ᶫᮏுኴ㸸EGUIDE ࣉࣟࢪ࢙ࢡࢺ㏆␥/஑ᕞ/ᮾ໭ㅮ⩦ 1㸪⤫ྜኻㄪ⑕ࡢ࢞࢖ࢻࣛ࢖ࣥㅮ⩦㸬࢜ࣥࣛ࢖ࣥ㸪2022.11.19.

ᶫᮏுኴ㸸EGUIDE ࣉࣟࢪ࢙ࢡࢺ㏆␥/஑ᕞ/ᮾ໭ㅮ⩦ 1㸪࠺ࡘ⑓ࡢ࢞࢖ࢻࣛ࢖ࣥㅮ⩦㸬࢜ࣥࣛ࢖ࣥ㸪2022.11.20.

ᶫᮏுኴ㸸EGUIDE ࣉࣟࢪ࢙ࢡࢺ㏆␥/஑ᕞ/ᮾ໭ㅮ⩦ 2㸪⤫ྜኻㄪ⑕ࡢ࢞࢖ࢻࣛ࢖ࣥㅮ⩦㸬࢜

̿ 98 ̿                   ϩ  ◊ ✲ ά ື ≧ ἣ                    ࣥࣛ࢖ࣥ㸪2022.11.19.
ᶫᮏுኴ㸸EGUIDE ࣉࣟࢪ࢙ࢡࢺ㏆␥/஑ᕞ/ᮾ໭ㅮ⩦ 2㸪࠺ࡘ⑓ࡢ࢞࢖ࢻࣛ࢖ࣥㅮ⩦㸬࢜ࣥࣛ࢖ࣥ㸪2022.11.20.

ᶫᮏுኴ㸸EGUIDE ࣉࣟࢪ࢙ࢡࢺ㛵ᮾ/ᅄᅜㅮ⩦㸪⤫ྜኻㄪ⑕ࡢ࢞࢖ࢻࣛ࢖ࣥㅮ⩦㸬࢜ࣥࣛ࢖ࣥ㸪2022.11.26.

ᶫᮏுኴ㸸EGUIDE ࣉࣟࢪ࢙ࢡࢺ㛵ᮾ/ᅄᅜㅮ⩦㸪࠺ࡘ⑓ࡢ࢞࢖ࢻࣛ࢖ࣥㅮ⩦㸬࢜ࣥࣛ࢖ࣥ㸪

2022.11.27.
ᶫᮏுኴ㸸➨ 17 ᅇ᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍ࢧࢸࣛ࢖ࢺ௻⏬㸪ᙜ஦⪅࣭ᐙ᪘ࡴࡅ࣮࣡ࢡࢩࣙࢵࣉࠕୖ
ᡭ࡞デᐹࡢཷࡅ᪉ࡢࢥࢶ㸦࠺ࡅࢥࢶ㸧ࠖࠥ⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻ 2022 ࡼࡾ㸬࢜ࣥࣛ࢖ࣥ㸪

2023.3.25.
ᶫᮏுኴ㸸➨ 17 ᅇ᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍ࢧࢸࣛ࢖ࢺ௻⏬㸪⤫ྜኻㄪ⑕ࡢㄆ▱♫఍ᶵ⬟㞀ᐖࡢᐃ࣮▷᫬㛫࡛ᐇ᪋ࡍࡿ⡆᫆࡞ㄆ▱♫఍ᶵ⬟ᐃࡢᐇ㝿࣮㸬࢜ࣥࣛ࢖ࣥ㸪2023.3.26.

 ◊ಟ఍ㅮᖌ
ᶫᮏுኴ㸸WS:ᘬ⏝ࡉࢀࡿ⢭⚄་Ꮫㄽᩥࡢ᭩ࡁ᪉㹼Editor ࡢ⤒㦂⤂௓࡜ಶู┦ㄯ㸬➨ 118 ᅇ᪥ᮏ⢭⚄⚄⤒Ꮫ఍Ꮫ⾡⥲఍࣮࣡ࢡࢩࣙࢵࣉ㸪⚟ᒸ㸪2022.6.17.

ᶫᮏுኴ㸸㍍⑕㸬኱㜰⢭⚄⛉デ⒪ᡤ༠఍㸪࠺ࡘ⑓἞⒪࢞࢖ࢻࣛ࢖ࣥㅮ⩦఍㸪࢜ࣥࣛ࢖ࣥ㸪2022.7.9.

ᶫᮏுኴ㸸⢭⚄⑓ᛶ㸬኱㜰⢭⚄⛉デ⒪ᡤ༠఍㸪࠺ࡘ⑓἞⒪࢞࢖ࢻࣛ࢖ࣥㅮ⩦఍㸪࢜ࣥࣛ࢖ࣥ㸪

2022.7.9.
ᶫᮏுኴ㸸࣮࣡ࢡࢩࣙࢵࣉࡢ┠ⓗ㸪ᴫㄝ㸬⍇⍈†⑓㝔㸪EGUIDE ࢡࣜࢽ࢝ࣝࣉࣛࢡࢸ࢕ࢫㅮ⩦఍㸪኱ὠ㸪2022.8.6.

ᶫᮏுኴ㸸἞⒪᢬ᢠᛶ⤫ྜኻㄪ⑕㸬2022 ᖺᗘᅜ❧⢭⚄࣭⚄⤒་⒪◊✲ࢭࣥࢱ࣮⢭⚄ಖ೺࡟㛵ࡍᶫᮏுኴ㸸⤫ྜኻㄪ⑕ࡢᶆ‽἞⒪◊ಟ࡜ࡣ㸬2022 ᖺᗘᅜ❧⢭⚄࣭⚄⤒་⒪◊✲ࢭࣥࢱ࣮⢭⚄ಖࡿᢏ⾡◊ಟ ➨ 1 ᅇ⤫ྜኻㄪ⑕ࡢᶆ‽἞⒪◊ಟ㸪࢜ࣥࣛ࢖ࣥ㸪2022.8.28.
೺࡟㛵ࡍࡿᢏ⾡◊ಟ ➨ 1 ᅇ⤫ྜኻㄪ⑕ࡢᶆ‽἞⒪◊ಟ㸪࢜ࣥࣛ࢖ࣥ㸪2022.8.28.
ᶫᮏுኴ㸸ඣ❺ᛮ᫓ᮇ㸬2022 ᖺᗘᅜ❧⢭⚄࣭⚄⤒་⒪◊✲ࢭࣥࢱ࣮⢭⚄ಖ೺࡟㛵ࡍࡿᢏ⾡◊ಟᶫᮏுኴ㸸࠺ࡘ⑓ࡢᶆ‽἞⒪◊ಟ࡜ࡣ㸬2022 ᖺᗘᅜ❧⢭⚄࣭⚄⤒་⒪◊✲ࢭࣥࢱ࣮⢭⚄ಖ೺࡟➨ 1 ᅇ࠺ࡘ⑓ࡢᶆ‽἞⒪◊ಟ㸪࢜ࣥࣛ࢖ࣥ㸪2022.9.4.
㛵ࡍࡿᢏ⾡◊ಟ ➨ 1 ᅇ࠺ࡘ⑓ࡢᶆ‽἞⒪◊ಟ㸪࢜ࣥࣛ࢖ࣥ㸪2022.9.4.
ᶫᮏுኴ㸸἞⒪᢬ᢠᛶ㸬኱㜰⢭⚄⛉デ⒪ᡤ༠఍㸪⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻࣛ࢖ࣥ 2022 ㅮ⩦ᶫᮏுኴ㸸㊃᪨ㄝ᫂ཬࡧ⌮ゎᗘグධ㸬⤫ྜኻㄪ⑕ࡢ࢞࢖ࢻࣛ࢖ࣥㅮ⩦㸪EGUIDE ࣉࣟࢪ࢙ࢡࢺ

఍㸪࢙࢘ࣈ࢜ࣥࣛ࢖ࣥ㛤ദ㸪࢜ࣥࣛ࢖ࣥ㸪2022.9.10.
㛵ᮾ NCNP ㅮ⩦㸪ᮾி㸪2022.10.2.
ᶫᮏுኴ㸸㊃᪨ㄝ᫂ཬࡧ⌮ゎᗘグධ㸬࠺ࡘ⑓ࡢ࢞࢖ࢻࣛ࢖ࣥㅮ⩦㸪EGUIDE ࣉࣟࢪ࢙ࢡࢺ㛵ᮾᶫᮏுኴ㸸἞⒪᢬ᢠᛶ⤫ྜኻㄪ⑕㸬⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻࣛ࢖ࣥㅮ⩦఍㸦EGUIDE ࣉࣟࢪ

NCNP ㅮ⩦㸪ᮾி㸪2022.10.16.
࢙ࢡࢺ㸧㸪➨ 44 ᅇ᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ᖺ఍㸪➨ 32 ᅇ᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ᖺ఍㸪➨52 ᅇ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ᖺ఍㸪➨ 6 ᅇ᪥ᮏ⢭⚄⸆Ꮫ఍⥲఍࣭Ꮫ⾡㞟఍ࡢ 4 Ꮫ఍ྜྠᖺ఍
㸦BPCNPNPPP4 Ꮫ఍ྜྠᖺ఍㸧㸪ᮾி㸪2022.11.6.
ᶫᮏுኴ㸸ㄆ▱♫఍ᶵ⬟㞀ᐖ᳨ᰝࡢព⩏࡜ᴫせ㸬➨ 17 ᅇ᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍ ࢧࢸࣛ࢖ࢺ௻
⏬㸸WS ⤫ྜኻㄪ⑕ࡢㄆ▱♫఍ᶵ⬟㞀ᐖࡢᐃ࣮▷᫬㛫࡛ᐇ᪋ࡍࡿ⡆᫆࡞ㄆ▱♫఍ᶵ⬟ᐃࡢᐇ㝿࣮㸪࢜ࣥࣛ࢖ࣥ㸪2023.3.26.
ᶫᮏுኴ㸸ㄆ▱♫఍ᶵ⬟㞀ᐖ᳨ᰝࡢ௒ᚋ࡜㉁␲ᛂ⟅㸬➨ 17 ᅇ᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍ ࢧࢸࣛ࢖ࢺ
௻⏬㸸WS ⤫ྜኻㄪ⑕ࡢㄆ▱♫఍ᶵ⬟㞀ᐖࡢᐃ࣮▷᫬㛫࡛ᐇ᪋ࡍࡿ⡆᫆࡞ㄆ▱♫఍ᶵ⬟ᐃࡢᐇ㝿࣮㸪࢜ࣥࣛ࢖ࣥ㸪2023.3.26.
ᯇᮏ⣧ᘺ㸸ㄆ▱ᶵ⬟㞀ᐖࡢゎㄝ࡜ά⏝౛㸬➨ 17 ᅇ᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍ ࢧࢸࣛ࢖ࢺ௻⏬㸸WS

̿ 99 ̿                    ⢭⚄ಖ೺◊✲ᡤᖺሗ ➨36ྕ                   ⤫ྜኻㄪ⑕ࡢㄆ▱♫఍ᶵ⬟㞀ᐖࡢᐃ࣮▷᫬㛫࡛ᐇ᪋ࡍࡿ⡆᫆࡞ㄆ▱♫఍ᶵ⬟ᐃࡢᐇ㝿࣮㸪

࢜ࣥࣛ࢖ࣥ㸪2023.3.26.
ఀ⸨㣁ጲ㸸♫఍άືホ౯࡜⑓๓᥎ᐃ IQ ࡢ
WS ⤫ྜኻㄪ⑕ࡢㄆ▱♫఍ᶵ⬟㞀ᐖࡢᐃ㸬➨ 17 ᅇ᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍ ࢧࢸࣛ࢖ࢺ௻⏬㸸ᐃ࣮▷᫬㛫࡛ᐇ᪋ࡍࡿ⡆᫆࡞ㄆ▱♫఍ᶵ⬟ᐃࡢᐇ㝿࣮㸬࢜ࣥࣛ࢖ࣥ㸪2023.3.26.
ᑠụ᫓⳯㸸⌧ᅾࡢ᥎ᐃ IQ ࡢᐃ㸦㢮ఝ㸧㸬➨ 17 ᅇ᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍ ࢧࢸࣛ࢖ࢺ௻⏬㸸WS⤫ྜኻㄪ⑕ࡢㄆ▱♫఍ᶵ⬟㞀ᐖࡢᐃ࣮▷᫬㛫࡛ᐇ᪋ࡍࡿ⡆᫆࡞ㄆ▱♫఍ᶵ⬟ᐃࡢᐇ㝿࣮㸪

࢜ࣥࣛ࢖ࣥ㸪2023.3.26.
᪂㇂ⱸⳀᯝ㸸⌧ᅾࡢ᥎ᐃ IQ ࡢᐃ㸦グྕ᥈ࡋ㸧㸬➨ 17 ᅇ᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍ ࢧࢸࣛ࢖ࢺ௻

⏬㸸WS ⤫ྜኻㄪ⑕ࡢㄆ▱♫఍ᶵ⬟㞀ᐖࡢᐃ࣮▷᫬㛫࡛ᐇ᪋ࡍࡿ⡆᫆࡞ㄆ▱♫఍ᶵ⬟ᐃࡢᐇ㝿࣮㸪࢜ࣥࣛ࢖ࣥ㸪2023.3.26.
㹄㸬ࡑࡢ௚

࠙ཷ㈹ࠚ
ᒣᙧᘯ㝯㸪⸨஭ඃᏊ㸪㜝 ཭ᜨ㸪㛗㇂ᕝᑦ⨾㸪ᶫᮏுኴ㸪୰ᕝ ఙ㸸➨ 118 ᅇ᪥ᮏ⢭⚄⚄⤒Ꮫ఍Ꮫ⾡⥲఍ඃ⚽Ⓨ⾲㈹㸪EGUIDE ࣉࣟࢪ࢙ࢡࢺ࡟ࡼࡿ⤫ྜኻㄪ⑕ᝈ⪅࣭࠺ࡘ⑓ᝈ⪅࡟ᑐࡍࡿእ
᮶ฎ᪉ࡢኚ໬㸪2022.6.17.
㉺ᬛ⤀୍㑻㸪ᶫᮏுኴ࡯࠿㸸JSNP Excellent Presentation Award for CINP㸪᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ 2022 ᖺ᭱ඃ⚽₇㢟㈹㸦㘠ᓥ㈹㸧㸪2022.6. ཷ㈹ㄽᩥ㸸Ochi S, Tagata H, Hasegawa N,
Yasui-Furukori N, Iga JI, Kashiwagi H, Kodaka F, Komatsu H, Tsuboi T, Tokutani A,
Numata S, Ichihashi K, Onitsuka T, Muraoka H, Iida H, Ohi K, Atake K, Kishimoto T, Hori
H, Takaesu Y, Takeshima M, Usami M, Makinodan M, Hashimoto N, Fujimoto M, Furihata
R, Nagasawa T, Yamada H, Matsumoto J, Miura K, Kido M, Hishimoto A, Ueno SI,
Watanabe K, Inada K, Hashimoto R: Clozapine Treatment Is Associated With Higher
Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other
Concomitant Psychotropics: A Real-World Nationwide Study. Int J Neuropsychopharmacol,

25(10):818-826, 2022.
ᯇᮏ⣧ᘺ㸸➨ 44 ᅇ᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ᖺ఍㸪➨ 32 ᅇ᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ᖺ఍㸪➨52 ᅇ᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍ᖺ఍㸪➨ 6 ᅇ᪥ᮏ⢭⚄⸆Ꮫ఍⥲఍࣭Ꮫ⾡㞟఍㸦BPCNPNPPP4 Ꮫ఍ྜྠᖺ఍㸧ඃ⚽₇㢟Ⓨ⾲㈹㸪⤫ྜኻㄪ⑕࣭཮ᴟᛶ㞀ᐖ࣭࠺ࡘ⑓࣭⮬㛢ࢫ࣌ࢡࢺ࣒ࣛ⑕ࡢከ᪋タ኱つᶍࢹ࣮ࢱ࡟ࡼࡿ⑌ᝈᶓ᩿ⓗ࡞኱⬻⓶㉁ᵓ㐀ࡢ㢮ఝᗘࡢゎᯒ㸪2022.11.
࠙ࡑࡢ௚ࠚ

ᶫᮏுኴ㸸ࣉࣞࢫ࣮ࣜࣜࢫ㸬⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻࣛ࢖ࣥ 2022 ᖺ∧බ㛤㸦᪥ᮏ⚄⤒⢭⚄⸆⌮Ꮫ఍㸧
㸪2022.5.11.

ᶫᮏுኴ㸸◊✲఍୺ᐓ. ➨ 18 ᅇ COCORO ྜྠ఍㆟㸪࢜ࣥࣛ࢖ࣥ㸪2022.6.5.
ᶫᮏுኴ㸸⥲ྜྖ఍㸬2022 ᖺᗘᅜ❧⢭⚄࣭⚄⤒་⒪◊✲ࢭࣥࢱ࣮⢭⚄ಖ೺࡟㛵ࡍࡿᢏ⾡◊ಟ
➨ 1 ᅇ⤫ྜኻㄪ⑕ࡢᶆ‽἞⒪◊ಟ㸪࢜ࣥࣛ࢖ࣥ㸪2022.8.28.

ᶫᮏுኴ㸸⥲ྜྖ఍㸬2022 ᖺᗘᅜ❧⢭⚄࣭⚄⤒་⒪◊✲ࢭࣥࢱ࣮⢭⚄ಖ೺࡟㛵ࡍࡿᢏ⾡◊ಟ
➨ 1 ᅇ࠺ࡘ⑓ࡢᶆ‽἞⒪◊ಟ㸪࢜ࣥࣛ࢖ࣥ㸪2022.9.4.

ᶫᮏுኴ㸸⥲ྜྖ఍㸬⤫ྜኻㄪ⑕ࡢ࢞࢖ࢻࣛ࢖ࣥㅮ⩦㸬EGUIDE ࣉࣟࢪ࢙ࢡࢺ㛵ᮾ NCNP ㅮ⩦㸪ᮾி㸪2022.10.2.

ᶫᮏுኴ㸸⥲ྜྖ఍㸬࠺ࡘ⑓ࡢ࢞࢖ࢻࣛ࢖ࣥㅮ⩦㸪EGUIDE ࣉࣟࢪ࢙ࢡࢺ㛵ᮾ NCNP ㅮ⩦㸪ᮾி㸪2022.10.16.

ᶫᮏுኴ㸸⥲ྜྖ఍㸬⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻࣛ࢖ࣥㅮ⩦఍㸦EGUIDE ࣉࣟࢪ࢙ࢡࢺ㸧㸪➨
44 ᅇ᪥ᮏ⏕≀Ꮫⓗ⢭⚄་Ꮫ఍ᖺ఍㸪➨ 32 ᅇ᪥ᮏ⮫ᗋ⢭⚄⚄⤒⸆⌮Ꮫ఍ᖺ఍㸪➨ 52 ᅇ᪥ᮏ⚄̿ 100 ̿                   ϩ  ◊ ✲ ά ື ≧ ἣ                    ⤒⢭⚄⸆⌮Ꮫ఍ᖺ఍㸪➨ 6 ᅇ᪥ᮏ⢭⚄⸆Ꮫ఍⥲఍࣭Ꮫ⾡㞟఍ࡢ 4 Ꮫ఍ྜྠᖺ఍㸦BPCNPNPPP4Ꮫ఍ྜྠᖺ఍㸧㸪ᮾி㸪2022.11.6.
ᶫᮏுኴ㸸◊✲఍୺ᐓ. ➨ 19 ᅇ COCORO ྜྠ఍㆟㸪࢜ࣥࣛ࢖ࣥ㸪2022.12.4.

ᶫᮏுኴ㸸ࣇ࢓ࢩࣜࢸ࣮ࢱ࣮. ➨ 17 ᅇ᪥ᮏ⤫ྜኻㄪ⑕Ꮫ఍ࢧࢸࣛ࢖ࢺ௻⏬㸪ᙜ஦⪅࣭ᐙ᪘ࡴࡅ
࣮࣡ࢡࢩࣙࢵࣉࠕୖᡭ࡞デᐹࡢཷࡅ᪉ࡢࢥࢶ㸦࠺ࡅࢥࢶ㸧ࠖࠥ⤫ྜኻㄪ⑕⸆≀἞⒪࢞࢖ࢻ 2022ࡼࡾ㸬࢜ࣥࣛ࢖ࣥ㸪2023.3.25.

̿ 101 ̿